Page last updated: 2024-11-04

hydroquinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID785
CHEMBL ID537
CHEBI ID17594
SCHEMBL ID15516
MeSH IDM0099980

Synonyms (343)

Synonym
BIDD:ER0340
phenol derivative, 4
chembl537 ,
1,4-dihydroxybenzene, xiii
hydroquinone, hq
bdbm26190
smr000059154
CHEBI:17594 ,
MLS000069815
DIVK1C_006865
1,4-hydroxybenzene
dihydroquinone
p benzendiol
para-hydroxyphenol
ccris 714
pyrogentistic acid
un2662
1,4-dihydroxy-benzol [german]
para-hydroquinone
hydrochinon
beta-quinol
1,4-dihydroxy-benzeen [dutch]
hsdb 577
solaquin forte
einecs 204-617-8
hydrochinon [czech, polish]
nsc 9247
alpha-hydroquinone
para-dioxybenzene
eldoquin forte
idrochinone [italian]
ai3-00072
para-dihydroxybenzene
eldopaque forte
quinnone
1,4-dihydroxybenzen [czech]
1,4-diidrobenzene [italian]
hydrop
reduced quinone
EU-0100577
D00073
eldoquin (tn)
hydroquinone (usp)
SPECTRUM_001757
eldoquin
hydroquinol
1,4-diidrobenzene
p-dioxybenzene
nci-c55834
arctuvin
1,4-dihydroxy-benzeen
usaf ek-356
HQ ,
hydroquinole
idrochinone
black and white bleaching cream
hidroquinone
nsc9247
eldopaque
benzene, p-dihydroxy-
melanex
.beta.-quinol
dihydroxybenzene
artra
tecquinol
he 5
wln: qr dq
benzoquinol
p-dihydroxybenzene
phiaquin
p-dioxobenzene
benzohydroquinone
derma-blanch
p-hydroquinone
1,4-dihydroxy-benzol
tenox hq
nsc-9247
p-hydroxyphenol
hydrochinon(czech, polish)
diak 5
1,4-dihydroxybenzen
.alpha.-hydroquinone
tequinol
NCGC00015523-01
lopac-h-9003
LOPAC0_000577
SPECTRUM5_001430
1,4-dihydrobenzoquinone
inchi=1/c6h6o2/c7-5-1-2-6(8)4-3-5/h1-4,7-8
NCGC00090880-01
123-31-9
C00530
benzene-1,4-diol
1,4-benzenediol
1,4-dihydroxybenzene
hydroquinone ,
p-benzenediol
quinol
4-hydroxyphenol
hydroquinone, reagentplus(r), >=99.5%
hydroquinone, meets usp testing specifications
MLS001074911
plq ,
NCGC00090880-03
NCGC00090880-04
KBIO2_002237
KBIO3_001511
KBIO1_001809
KBIO2_007373
KBIOGR_001246
KBIOSS_002237
KBIO2_004805
SPBIO_001883
SPECTRUM4_000633
SPECTRUM2_001672
SPECPLUS_000769
SPECTRUM3_000656
SPECTRUM1504237
BSPBIO_002291
NCGC00090880-05
NCGC00090880-02
STK397446
hydroquinone, reagentplus(r), >=99%
NCGC00015523-03
094CADDB-59BF-4EDF-B278-59791B203EA2
HMS2093E08
H 9003
NCGC00015523-07
BMSE000293
hydroquinone [un2662] [poison]
H0186
HMS1922H15
NCGC00015523-02
AKOS000119003
HMS3261D16
hydrochinone
tox21_300015
NCGC00259894-01
NCGC00254037-01
tox21_202345
nsc-758707
nsc758707
pharmakon1600-01504237
tox21_110169
cas-123-31-9
dtxsid7020716 ,
dtxcid70716
S4580
CCG-39082
NCGC00015523-05
NCGC00015523-06
NCGC00015523-04
NCGC00015523-12
NCGC00015523-10
NCGC00015523-11
NCGC00015523-08
NCGC00015523-09
4-dihydroxybenzene
hydroquinone [usp]
unii-xv74c1n1ae
ec 204-617-8
xv74c1n1ae ,
epiquin
sunvanish
FT-0606877
LP00577
tri-luma component hydroquinone
hydroquinone [vandf]
hydroquinone [mi]
hydroquinone component of tri-luma
hydroquinone [iarc]
butylhydroxyanisole impurity a [ep impurity]
hydroquinone [who-dd]
hydroquinone [mart.]
hydroquinone [usp monograph]
hydroquinone [hsdb]
hydroquinone [orange book]
hydroquinone [usp-rs]
hydroquinone [inci]
EPITOPE ID:116206
BP-21160
SCHEMBL15516
NCGC00015523-13
4E3H
tox21_110169_1
tox21_500577
NCGC00261262-01
1,4 benzenediol
hydroquinon
hydroq uinone
p-dihydroxy benzene
4-hydroxyphenyl alcohol
un 2662
artra (salt/mix)
eldopacque
black & white bleaching cream
p-dihydroquinone
HY-B0951
AB00053361_08
mfcd00002339
DB09526
J-004910
J-521469
F1908-0167
hydroquinone, certified reference material, tracecert(r)
SR-01000075920-1
sr-01000075920
hydroquinone, saj special grade, >=99.0%
hydroquinone, saj first grade, >=99.0%
hydroquinone, united states pharmacopeia (usp) reference standard
b-quinol
hydroquinone for synthesis
p-hydroxybenzene
hydroquinone gr
hydroquinoue
a-hydroquinone
p-quinol
p-phenylenediol
bq(h)
1,4-benzoquinol
hydroquinone, lr, >=99%
hydroquinone, usp, 99.0-100.5%
hydroquinone, puriss., 99.0%
hydroquinone, pharmaceutical secondary standard; certified reference material
SR-01000075920-4
SBI-0050559.P002
Z57127551
Q419164
4-benzenediol
hydroquinone,(s)
Q27102742
AM10548
EN300-18053
SDCCGSBI-0050559.P003
NCGC00015523-19
1,4-dihydroxybenzene quinol
benzene-1,4-diol (hydroquinone)
quinol; 1,4-benzenediol; 1,4-dihydroxybenzene
eb5 age spot treatment
dr. lightening ultra-potent facial
idole carrot
light the way
african formula black
seequin 2
hydroquinone (usp monograph)
nu-derm clearskin bleaching and corrector
meditowelilluminating skin brightening
plus skin lightening cream
dermisaskin fade vitamin c infused
zo medical melamin-c skin bleaching and correcting with vitamin c hydroquinone
141067 hydroquinone 8%
nu-derm clear
sh18
141055 hydroquinone 6%
movate lemon
exence white
pure valley miracle age spot
activator light
neovacomplex hq plus
skin lightener
nova complex hq
hydroquinone 8%
obagi-c rx system c-clarifying serum normal to oily
gold cosmetics bleach cream silver
brightenlightening
advanced dual complex fademaximum strength plus
clear action
condition and enhance clearskin bleaching and corrector
active 4
hydroquinone gel
plexaderm dark spot fade gel
hqla
medisilkenight
african formula carrot
clarite 4
precious beauty skin lightening
141011 hydroquinone 6%
zo skin health pigment control creme hydroquinone
nu-derm blender
double white
rejuvaderm medispa fading
caro light
hydroquinone (usp-rs)
clear-n-smooth super-ultimate
clear-n-smooth ultimate
gold cosmetics bleach cream forte
hydroquinone (iarc)
md acne medicated dark spot remover
elastiderm decolletage skin lightening complexchest and neck
hydroquinone 6%
zo skin health pigment control program plus hydroquinone
skin lighteningrodan fields
image md lightening rx
hydroquinone 8%.
balancer
clear-n-smooth plus
corrector light
piona
movate carrot
divine derrier skin bleaching cream
obagi c rx system c clarifying serum
body fade crememaximum strength
skin lightening complex
hydroquinone (mart.)
teatrical pro-aclarant skin lightening
scarlight md
olivia quido blemish eraser
hq plus brightening creamvi derm
obagi-c rx system c-therapy nightskin lightening with vitamins c and e
gold cosmetics bleach cream
141010 hydroquinone 4%
clear-n-smooth ultramax
miraclefade
hydro-q
zo skin health pigment control plus brightening creme hydroquinone plus vitamin c
obagi-c
symba skin lightening
ageless total skin bleaching serum
idole black
i-max lightening 5
hydroquinone cream
essential fade complex
skin beautifying milk
nu-derm blenderskin lightener and blending
zo skin health pigment control plus blending creme hydroquinone
gold cosmetics adi clear
dr. throwers skin lightening moisturizing
141030 hydroquinone 8%
butylhydroxyanisole impurity a (ep impurity)
obagi-c rx system c-clarifying serum normal to oilyskin lightening serum with vitamin c
hydroquinone 4%
vividly brilliant perfecting
condition and enhance blenderskin lightener and blending
hydroquinone time release
supermax
olivia quido skincare blemish eraser
seequin 4
skin lightening cream
clear-n-smooth supermax
hot movate
obagi-c rx system c-therapy night
dark spot lightening cream
ultimate skin lightening cream

Research Excerpts

Overview

Hydroquinone is a commonly used depigmenting agent in clinical practice for treating hyperpigmentation. Hydroquinone (HQ) is a major benzene metabolite, which is a well-known haematotoxic and carcinogenic agent associated with malignancy in occupational environments.

ExcerptReferenceRelevance
"Hydroquinone is a commonly used depigmenting agent in clinical practice for treating hyperpigmentation."( Hyperpigmentation: Looking beyond hydroquinone.
Charoo, NA, 2022
)
1.72
"Hydroquinones are a class of organic compounds abundant in nature that result from the full reduction of the corresponding quinones. "( Inhibition of Urease by Hydroquinones: A Structural and Kinetic Study.
Cianci, M; Ciurli, S; Mazzei, L, 2022
)
2.47
"Hydroquinone is a cytotoxic, immunotoxic, carcinogenic and pro-oxidative component of tobacco smoke."( Regulation of oxidative stress and inflammatory responses in human retinal pigment epithelial cells.
Harju, N, 2022
)
1.44
"Hydroquinone (HQ) is an important metabolites of benzene in the body, and it has been found to result in cellular DNA damage, mutation, cell cycle imbalance, and malignant transformation. "( JNK1 activated pRb/E2F1 and inhibited p53/p21 signaling pathway is involved in hydroquinone-induced pathway malignant transformation of TK6 cells by accelerating the cell cycle progression.
Chen, L; Cui, Z; Gao, Y; Guo, P; Luo, H; Qiu, W; Sun, M; Tang, H; Yu, L; Zhu, D, 2023
)
2.58
"Hydroquinone is a major benzene metabolite, which is a well-known haematotoxic and carcinogenic agent associated with malignancy in occupational environments. "( Hydroquinone: environmental pollution, toxicity, and microbial answers.
Enguita, FJ; Leitão, AL, 2013
)
3.28
"Hydroquinone (HQ) is a chemical compound that inhibits the functions of melanocytes and has long been known for its skin-whitening effect. "( Analysis of the effects of hydroquinone and arbutin on the differentiation of melanocytes.
Akamatsu, H; Date, Y; Hasegawa, S; Inoue, Y; Matsunaga, K; Mizutani, H; Nakata, S; Yamada, T, 2013
)
2.13
"Hydroquinone (HQ) is a well-known environmental carcinogen and exposure of humans to HQ can also occur through plant foods, cosmetics, and tobacco products. "( Hydroquinone stimulates cell invasion through activator protein-1-dependent induction of MMP-9 in HepG2 human hepatoma cells.
Lee, SO; Yu, MH, 2016
)
3.32
"Hydroquinone (HQ) is an important benzene-derived metabolite associated with acute myelogenous leukemia risk. "( Hydroquinone induces DNA hypomethylation-independent overexpression of retroelements in human leukemia and hematopoietic stem cells.
Bollati, V; Conti, A; Dieci, G; Favero, C; Fustinoni, S; Lazzari, L; Motta, V; Ragni, E; Rota, F, 2016
)
3.32
"Hydroquinone (HQ) functions as a skin-whitening agent, but it has the potential to cause dermatitis. "( Synthesis and characterization of hydroquinone fructoside using Leuconostoc mesenteroides levansucrase.
Kang, J; Kim, D; Kim, DW; Kim, N; Kim, YM; Nam, SH, 2009
)
2.07
"Hydroquinone is a component of cigarette smoke and serum copper level is increased in smokers."( Effect of copper-hydroquinone complex on oxidative stress-related parameters in human erythrocytes (in vitro).
Chakraborty, R; Mitra, PK; Nayak, C; Saha, S; Sarkar, C, 2009
)
1.41
"Hydroquinone (HQ) is a metabolite of benzene, and in combination with phenol (PHE), reproduces benzene myelotoxicity. "( Role of hydroquinone-thiol conjugates in benzene-mediated toxicity.
Bratton, SB; Kuhlman, CL; Lau, SS; Monks, TJ, 2010
)
2.24
"Hydroquinone (HQ) is a major metabolite of benzene and has been used as an antioxidant, a stabilizer, a photographic reducer, and an ingredient in skin lighteners. "( Risk assessment of hydroquinone: differential responses of cell growth and lethality correlated to hydroquinone concentration.
Cho, YH; Chung, HW; Kang, SJ; Kim, BM; Kim, YJ; Lee, YJ; Woo, HD, 2009
)
2.12
"Hydroquinone (HQ) is a benzene metabolite that is involved in hematopoiesis via its accumulation into bone marrow. "( The pro-apoptotic effect of hydroquinone in human neutrophils and eosinophils.
Kim, IS; Lee, JS; Yang, EJ; Yun, CY, 2011
)
2.11
"Hydroquinone is an aromatic compound that functions in cosmetics as an antioxidant, fragrance, reducing agent, or polymerization inhibitor. "( Final amended safety assessment of hydroquinone as used in cosmetics.
Andersen, FA; Belsito, DV; Bergfeld, WF; Hill, RA; Klaassen, CD; Liebler, DC; Marks, JG; Shank, RC; Slaga, TJ; Snyder, PW,
)
1.85
"Hydroquinone is a phenolic metabolite of benzene, a known human carcinogen. "( Hydroquinone, a benzene metabolite, and leukemia: a case report and review of the literature.
Brautbar, N; Regev, L; Wu, M; Zlotolow, R, 2012
)
3.26
"Hydroquinone (HQ) is an environmental contaminant which causes immune toxicity. "( In vivo hydroquinone exposure alters circulating neutrophil activities and impairs LPS-induced lung inflammation in mice.
de Lima, WT; de Melo Loureiro, AP; de Oliveira, TF; Farsky, SH; Filho, Wdos R; Hebeda, CB; Ribeiro, AL; Santos, AM; Shimada, AL, 2011
)
2.25
"Hydroquinone (HQ) is a major benzene metabolite, which is produced after benzene biotransformation. "( Hydroquinone-induced apoptosis of human lymphocytes through caspase 9/3 pathway.
Kim, IS; Lee, JS; Yang, EJ, 2012
)
3.26
"Hydroquinone (HQ) is an environmental pollutant and a component of cigarette smoke that causes immunosuppressive effects."( In vivo hydroquinone exposure impairs MCP-1 secretion and monocyte recruitment into the inflamed lung.
Bolonheis, SM; Farsky, SH; Ferraz-de-Paula, V; Hebeda, CB; Ribeiro, AL; Shimada, AL, 2012
)
1.53
"Hydroquinone is a potent inhibitor of the fibrillar aggregation of beta-amyloid as determined in two different assay systems."( Synthesis of (-)-5,8-dihydroxy-3R-methyl-2R-(dipropylamino)-1,2,3,4-tetrahydronaphthalene: an inhibitor of beta-amyloid(1-42) aggregation.
Boyd, RE; Chen, R; Conway, KA; Lee, DH; Luo, C; Nortey, SO; Parker, MH; Reitz, AB; Ross, TM; Scott, MK, 2002
)
1.04
"Hydroquinone (HQ) is a chemical used as a reducing agent, antioxidant, polymerization inhibitor, and chemical intermediate. "( The role of thiol reduction in hydroquinone-induced apoptosis in HEK293 cells.
Fu, JL; Shen, DX; Shi, X; Zhang, YM; Zhou, ZC, 2003
)
2.05
"Hydroquinone is a myelotoxin that is found in many foods and is also formed through the metabolism of benzene. "( GSTM1, GSTT1, and GSTP1 genotypes and the genotoxicity of hydroquinone in human lymphocytes.
Duarte Silva, I; Faber, A; Gaspar, J; Rueff, J; Silva, Mdo C, 2004
)
2.01
"Hydroquinone (HQ) is an important industrial chemical that also occurs naturally in foods and in the leaves and bark of a number of plant species. "( Metabolic rate constants for hydroquinone in F344 rat and human liver isolated hepatocytes: application to a PBPK model.
Corley, RA; English, JC; Poet, TS; Wu, H, 2004
)
2.06
"Hydroquinone is a benzene-derived metabolite. "( Involvement of oxidative stress in hydroquinone-induced cytotoxicity in catalase-deficient Escherichia coli mutants.
Horita, M; Kira, S; Masuoka, N; Sano, K; Tsutsui, K; Wang, DH, 2005
)
2.05
"Hydroquinone (HQ) is a common water-soluble constituent of foods, an ingredient in skin lightening preparations, a photographic developer, and an antioxidant used in the preparation of industrial polymers. "( Hydroquinone: acute and subchronic toxicity studies with emphasis on neurobehavioral and nephrotoxic effects.
Bernard, LG; English, JC; O'Donoghue, JL; Topping, DC, 2007
)
3.23
"Hydroquinone is a toxic compound and a major benzene metabolite. "( Hydroquinone, a reactive metabolite of benzene, reduces macrophage-mediated immune responses.
Cho, JY; Chun, T; Kim, JY; Lee, JY; Lee, YG; Rhee, MH; Shin, WC, 2007
)
3.23
"Hydroquinone is a synthetically produced as well as naturally occurring chemical."( Induction of a cell-survival adaptive response in MRC-5 cells by hydroquinone.
Huang, H; Li, X; Liu, J; Tang, S; Yang, L; Zhuang, Z, 2008
)
1.31
"Hydroquinone (HQ) is a nonvolatile chemical used in the photographic, rubber, chemical, and cosmetic industries. "( Human exposure to naturally occurring hydroquinone.
Deisinger, PJ; English, JC; Hill, TS, 1996
)
2.01
"Hydroquinone (HQ) is a major metabolite of benzene and is present in large quantities in cigarette tar as a result of the combustion of tobacco leaf pigments. "( Inhibition of human T lymphoblast proliferation by hydroquinone.
Freed, BM; Geiselhart, L; Lawrence, DA; Li, Q; Mittler, JN; Mudzinski, SP, 1996
)
1.99
"Hydroquinone is a ubiquitous chemical readily available as monographed in cosmetic and nonprescription forms for skin lightening, and is an important industrial chemical. "( Human in vivo and in vitro hydroquinone topical bioavailability, metabolism, and disposition.
Cox, R; Hui, X; Maibach, HI; Melendres, J; Quan, D; Serranzana, S; Wester, RC; Zhai, H, 1998
)
2.04
"Hydroquinone is a well known reagent used in the treatment of pigmentation disorders. "( Efficacy of topical treatment of pigmentation skin disorders with plant hydroquinone glucosides as assessed by quantitative color analysis.
Barel, A; Clarys, P, 1998
)
1.98
"Hydroquinone (HQ) is a high-volume commodity chemical used as a reducing agent, antioxidant, polymerization inhibitor, and chemical intermediate. "( The toxicology of hydroquinone--relevance to occupational and environmental exposure.
DeCaprio, AP, 1999
)
2.08
"Hydroquinone (HQ) is a potential human carcinogen to which many people are exposed. "( Carcinogenicity of a nephrotoxic metabolite of the "nongenotoxic" carcinogen hydroquinone.
Everitt, JI; Kleymenova, E; Lau, SS; Monks, TJ; Walker, CL, 2001
)
1.98

Effects

Hydroquinone (H2Q) has been marketed in skin-lightening products for almost 50 years and remains as the most frequently used whitening constituent in the category. Hydroquinone has significant toxicity to human bronchial epithelial cells and causes DNA damage.

ExcerptReferenceRelevance
"Hydroquinone has pharmacological uses in disorders of pigmentation because of its ability to competitively inhibit the enzyme tyrosinase. "( Hydroquinone: myths and reality.
Al-Niaimi, F; Ali, FR; Searle, T, 2021
)
3.51
"Hydroquinone (H2Q) has been observed to compete with the oxidation of substrates 2,4,6-tribromophenol (2,4,6-TBP) and 2,4,6-trichlorophenol (2,4,6-TCP) catalyzed by the dehaloperoxidase-hemoglobin (DHP) from Amphitrite ornata in the presence of H2O2. "( The regulatory implications of hydroquinone for the multifunctional enzyme dehaloperoxidase-hemoglobin from Amphitrite ornata.
Franzen, S; Zhao, J, 2013
)
2.12
"Hydroquinone has been marketed in skin-lightening products for almost 50 years and remains as the most frequently used whitening constituent in the category. "( Hydroquinone for skin lightening: safety profile, duration of use and when should we stop?
Tse, TW, 2010
)
3.25
"Hydroquinone (HQ) has been used as a skin-lightening cosmetic ingredient, while it has been known that HQ shows sensitizing potential and cross-reactivity toward a strong sensitizer, p-phenylenediamine (PPD). "( Experimental study on cross-reactivity of alpha-arbutin toward p-phenylenediamine and hydroquinone in guinea pigs.
Itoh, M; Kuriki, T; Nishimura, T; Nomura, K; Sugimoto, K; To-o, K, 2010
)
2.03
"Hydroquinone has been the standard prescription agent for skin lightening; however, its use recently has become controversial. "( Evaluation of a kojic acid, emblica extract, and glycolic acid formulation compared with hydroquinone 4% for skin lightening.
Bhushan, P; Draelos, ZD; Oresajo, C; Pillai, S; Yatskayer, M, 2010
)
2.03
"Hydroquinone has been a cornerstone for the treatment of hyperpigmentation; however, concerns regarding adverse effects have prompted a search for alternative agents."( New horizons in treating disorders of hyperpigmentation in skin of color.
Geria, AN; Halder, RM; Konda, S, 2012
)
1.1
"Hydroquinone ban has caused investigators to search for alternative depigmenting agents for the treatment of melasma in recent years."( Successful treatment of hydroquinone-resistant melasma using topical methimazole.
Abbas, O; Barouti, N; Chedraoui, A; Ghosn, S; Malek, J; Nikolic, D,
)
1.16
"Hydroquinone has been successfully used to treat hyperpigmentation disorders for many years. "( Lustra, Lustra-AF and Alustra.
Gupta, AK; Ryder, JE, 2003
)
1.76
"Hydroquinone (HQ) has been used since the 1950s in commercially available over-the-counter skin lightener products and since the 1960s as a commercially available medical product. "( Hydroquinone and its analogues in dermatology - a risk-benefit viewpoint.
O'Donoghue, JL, 2006
)
3.22
"Hydroquinone has significant toxicity to human bronchial epithelial cells and causes DNA damage. "( Possible role of DNA polymerase beta in protecting human bronchial epithelial cells against cytotoxicity of hydroquinone.
Fang, DK; He, Y; Hu, DL; Ji, WD; Liang, HR; Liu, YM; Sha, Y; Tang, DS; Tang, HW; Tu, XZ; Yang, JP; Yuan, JH; Zhu, ZY; Zhuang, ZX, 2007
)
2
"Hydroquinone has been shown reproducibly to induce benign neoplasms in the kidneys of male F344 rats dosed orally either by gavage (25 and 50 mg/kg body weight) or diet (0.8%)."( Hydroquinone: an evaluation of the human risks from its carcinogenic and mutagenic properties.
McGregor, D, 2007
)
2.5
"Hydroquinone exposure has been reported by the National Toxicology Program (NTP) to produce renal tubule adenomas and to exacerbate spontaneous chronic progressive nephropathy (CPN) in male F344 rats. "( Relationship of hydroquinone-associated rat renal tumors with spontaneous chronic progressive nephropathy.
English, JC; Hard, GC; Whysner, J; Williams, GM; Zang, E,
)
1.92
"Hydroquinone (HQ) has been reported to produce chromosomal effects in some in vivo and in vitro animal models. "( Lack of induction of micronuclei in human peripheral blood lymphocytes treated with hydroquinone.
Doepker, CL; Dumont, KW; English, JC; O'Donoghue, J, 2000
)
1.97

Actions

Hydroquinone (HQ) may activate oxygen via redox cycles in biological systems and may also deplete glutathione (GSH) Hydroquinone exhibited a lower penetration through senescent skin than young skin.

ExcerptReferenceRelevance
"Hydroquinone exhibited a lower penetration through senescent skin than young skin."( The risk of hydroquinone and sunscreen over-absorption via photodamaged skin is not greater in senescent skin as compared to young skin: nude mouse as an animal model.
Aljuffali, IA; Chen, WY; Fang, JY; Hung, CF; Shih, HC, 2014
)
1.5
"Hydroquinone could inhibit the production of melanin and eliminate the discolorations of skin."( The Use of Cellulose Nanocrystals for Potential Application in Topical Delivery of Hydroquinone.
Mohammadi, M; Taheri, A, 2015
)
1.36
"Hydroquinone (HQ) may activate oxygen via redox cycles in biological systems and may also deplete glutathione (GSH). "( The role of GSH depletion and toxicity in hydroquinone-induced development of enzyme-altered foci.
Högberg, J; Lundberg, I; Rannug, A; Stenius, U; Walles, S; Warholm, M, 1989
)
1.98
"Hydroquinone failed to inhibit arteriolar dilation in situ."( Uncertain role of endothelium-derived relaxing factor in mesenteric arterioles of cats and rabbits.
Bing, RJ; Saeed, M; Sütsch, G, 1988
)
1

Treatment

Hydroquinone is the basic treatment that its effect alone and in combination with other medications has been proven. Hydroquinone treatment impaired LPS-induced nitric oxide (NO), tumour necrosis factor α (TNF-α) and IL-6 secretions by neutrophils. Treatment with hydroquinone (100 mg/kg, i.p.) for 5 d had a similar hypopigmenting effect to that of high dose glycine.

ExcerptReferenceRelevance
"Hydroquinone is the basic treatment that its effect alone and in combination with other medications has been proven."( Comparison of therapeutic effects of conventional and liposomal form of 4% topical hydroquinone in patients with melasma.
Banihashemi, M; Dorri, M; Golnouri, F; Jaafari, MR; Marhamati, H; Salehi, M; Taghavi, F; Zabolinejad, N, 2019
)
1.46
"Hydroquinone treatment induced the membrane expression of cell adhesion molecules (CAMs) from the immunoglobulin superfamilies ICAM-1 (intercellular), VCAM-1(vascular) and PECAM-1 (platelet endothelial) and induced the secretion of cytokines interleukin-1β (IL-1β) and tumour necrosis factor-α (TNF-α)."( Hydroquinone stimulates inflammatory functions in microvascular endothelial cells via NF-κB nuclear activation.
Curi, R; Farsky, SH; Hebeda, CB; Pinedo, FJ; Vinolo, MA, 2011
)
2.53
"Hydroquinone treatment impaired LPS-induced nitric oxide (NO), tumour necrosis factor α (TNF-α), interleukin (IL)-1β and IL-6 secretions by neutrophils."( Intracellular mechanisms of hydroquinone toxicity on endotoxin-activated neutrophils.
Bolonheis, SM; Farsky, SH; Ferreira, ZF; Hebeda, CB; Muscará, MN; Pinedo, FJ; Teixeira, SA, 2012
)
1.39
"Hydroquinone treatment produces a specific inhibition of catalase in the tumor and a higher degree of oxygenation at this level."( Biophysical radiosensitization.
Apetroae, M; Vladescu, C, 1983
)
0.99
"Hydroquinone (HQ) treatment 24 or 48 h after diethylnitrosamine (DEN) initiation reduced the number of glutathione S-transferase-P (GST-P)-positive hepatocytes in situ."( Selective toxicity in putative preneoplastic hepatocytes: a comparison of hydroquinone and duroquinone.
Högberg, J; Stenius, U; Warholm, M, 1993
)
1.24
"Treatment of hydroquinone, the histone deacetylase activity and the mRNA expression of HDAC1 and HDAC2 were increased in a certain time range. "( [Effect of hydroquinone on the histone deacetylase in human bone marrow mononuclear cells].
Ge, HP; Hong, LL; Shi, YF; Xu, X; Yan, QX; Yu, K, 2016
)
1.19
"Treatment with hydroquinone (100 mg/kg, i.p.) for 5 d had a similar hypopigmenting effect to that of high dose glycine."( Glycine inhibits melanogenesis in vitro and causes hypopigmentation in vivo.
Ishii, F; Ishikawa, M; Kawase, I, 2007
)
0.68
"Pretreatment with hydroquinone (HQ) at concentrations ranging from picomolar to micromolar for 30 min resulted in a 1.5- to 4.6-fold enhancement in colonies formed in response to rGM-CSF that was due to an increase in granulocyte/macrophage colonies."( Synergistic action of the benzene metabolite hydroquinone on myelopoietic stimulating activity of granulocyte/macrophage colony-stimulating factor in vitro.
Colagiovanni, DB; Henry, VA; Irons, RD; Stillman, WS, 1992
)
0.87
"Treatment with hydroquinone alone or in combination with phenol produced a 3-fold increase in micronucleated cells over background."( Two benzene metabolites, catechol and hydroquinone, produce a synergistic induction of micronuclei and toxicity in cultured human lymphocytes.
Eastmond, DA; Robertson, ML; Smith, MT, 1991
)
0.89

Toxicity

Hydroquinone (HQ), a toxic bone marrow (BM) metabolite of BZ, causes time- and concentration-dependent inhibition of processing of the 34-Kd pre-interleukin-1 alpha. HQ was more toxic than arbutin. A cream containing 4% hydroquinone, 10% buffered glycolic acid, vitamins C and E and sunscreen is safe and effective in the treatment of melasma.

ExcerptReferenceRelevance
"It has long been recognized that benzene exposure produces disparate toxic responses among different species or even among different strains within the same species."( Evidence for strain-specific differences in benzene toxicity as a function of host target cell susceptibility.
Neun, DJ; Penn, A; Snyder, CA, 1992
)
0.28
"Two patients with exogenous ochronosis, an unfamiliar side effect of hydroquinone-containing bleaching creams, are presented."( [Exogenous ochronosis, a little-known side effect of hydroquinone-containing ointments].
Dekker, SK; Menke, HE; Noordhoek Hegt, V; Pavel, S; Westerhof, W, 1992
)
0.77
" Hydroquinone (HQ), a toxic bone marrow (BM) metabolite of BZ, causes time- and concentration-dependent inhibition of processing of the 34-Kd pre-interleukin-1 alpha (IL-1 alpha) to the 17-Kd mature cytokine in murine P388D1 macrophages and BM stromal macrophages, as measured by Western immunoblots of cell lysate proteins using a polyclonal rabbit antimurine IL-1 alpha antibody."( Role for interleukin-1 (IL-1) in benzene-induced hematotoxicity: inhibition of conversion of pre-IL-1 alpha to mature cytokine in murine macrophages by hydroquinone and prevention of benzene-induced hematotoxicity in mice by IL-1 alpha.
Kalf, GF; Renz, JF, 1991
)
1.39
" The lack of toxicity in these specimens suggests that residual contents of inhibitor and initiator are too low to cause toxic effects on choroidal fibroblasts."( Cytotoxic effects of residual chemicals from polymeric biomaterials for artificial soft intraocular lenses.
Barrett, GD; Chirila, TV; Constable, IJ; Thompson, DE; Walker, LN, 1991
)
0.28
" In this model HQ could be shown to be selectively toxic to GGT-negative cells in the presence of extracellular GSH."( The role of GSH depletion and toxicity in hydroquinone-induced development of enzyme-altered foci.
Högberg, J; Lundberg, I; Rannug, A; Stenius, U; Walles, S; Warholm, M, 1989
)
0.54
" However, susceptibility to these toxic effects may be related to a balance between activation (phase I) and detoxication (phase II) reactions."( In vitro conjugation of benzene metabolites by human liver: potential influence of interindividual variability on benzene toxicity.
Medinsky, MA; Schlosser, P; Seaton, MJ, 1995
)
0.29
" In vivo and in vitro experiments show that hydroquinone is the most toxic compound, whereas diphenols are more toxic than phenol."( Structure-activity relationship of phenolic compounds (phenol, pyrocatechol and hydroquinone) on natural lymphocytotoxicity of carp (Cyprinus carpio).
Deschaux, P; Khan, NA; Taysse, L; Troutaud, D, 1995
)
0.78
" HQ was introduced into these formulations to provide a safe and effective alternative to mercury and other less effective ingredients."( Lack of nephrotoxicity and renal cell proliferation following subchronic dermal application of a hydroquinone cream.
David, RM; English, JC; Moyer, C; O'Donoghue, JL; Totman, LC, 1998
)
0.52
"A cream containing 4% hydroquinone, 10% buffered glycolic acid, vitamins C and E, and sunscreen is safe and effective in the treatment of melasma."( Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma.
Guevara, IL; Pandya, AG, 2003
)
0.93
" In all treatment groups, skin-related adverse events were mild or moderate and transient."( Mequinol 2%/tretinoin 0.01% solution: an effective and safe alternative to hydroquinone 3% in the treatment of solar lentigines.
Jarratt, M, 2004
)
0.55
" Several hypotheses have been postulated on how benzene exerts its toxic and carcinogenic effects, one idea being that following metabolism to more reactive species it can react with DNA to form adducts which subsequently give rise to mutations."( Comparison of the repair of DNA damage induced by the benzene metabolites hydroquinone and p-benzoquinone: a role for hydroquinone in benzene genotoxicity.
Farmer, PB; Gaskell, M; McLuckie, KI, 2005
)
0.56
" only 3 patients (1%) withdrew from the study due to treatment-related adverse events (AEs)."( Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma.
Jones, T; Rich, P; Smith, S; Torok, HM; Tschen, E, 2005
)
1.77
" Recently, attention has focused on the estrogen-like and carcinogenic adverse effects of BPA and HQ."( Cytotoxicity and apoptosis-inducing activity of bisphenol A and hydroquinone in HL-60 cells.
Fujisawa, S; Kadoma, Y; Sakagami, H; Terasaka, H,
)
0.37
"5%) discontinued the study due to treatment-related adverse events (AEs)."( A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads.
Baumann, L; Jarret, M; Jones, T; Lowe, N; Martin, D; Menter, A; Pariser, D; Rich, P; Taylor, S; Torok, H; Tschen, E; Weiss, J; Wieder, J,
)
0.13
" The acute oral LD50 value for both sexes combined was >375 mg/kg."( Hydroquinone: acute and subchronic toxicity studies with emphasis on neurobehavioral and nephrotoxic effects.
Bernard, LG; English, JC; O'Donoghue, JL; Topping, DC, 2007
)
1.78
" Considering that many toxic effects of AhR ligands are dependent on AhR activation, our first objective was to determine if benzene, hydroquinone (HQ) or benzoquinone (BQ) could activate the AhR."( Investigating the role of the aryl hydrocarbon receptor in benzene-initiated toxicity in vitro.
Badham, HJ; Winn, LM, 2007
)
0.54
"A microcalorimetric technique based on bacterial heat-output was explored to evaluate the toxic effect of different diphenol species on the growth of Escherichia coli (E."( A microcalorimetric method for studying the toxic effect of different diphenol species on the growth of Escherichia coli.
Bramanti, E; Chen, H; Choi, MM; Djak, A; Tian, L; Wang, F; Wang, Y; Yao, J, 2007
)
0.34
" Safety was assessed through the reporting of adverse events."( A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma.
Chan, R; Chang, SE; Kerrouche, N; Lee, ES; Lee, MH; Legarda-Montinola, F; Leow, YH; Park, KC; Shek, S; Tay, YK; Thomas, G; Tsai, RY; Tsai, TH; Verallo-Rowell, V, 2008
)
0.55
" More patients had related adverse events on TC (63/129, 48."( A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma.
Chan, R; Chang, SE; Kerrouche, N; Lee, ES; Lee, MH; Legarda-Montinola, F; Leow, YH; Park, KC; Shek, S; Tay, YK; Thomas, G; Tsai, RY; Tsai, TH; Verallo-Rowell, V, 2008
)
0.55
" We postulated that the TRP-2 beneficial effect observed in WM35 cells in the oxidative stress situation may relate to quinone metabolization and, more precisely, to the ability of TRP-2 to clear off related toxic metabolites, resulting in a global redox status modification."( TRP-2 expression protects HEK cells from dopamine- and hydroquinone-induced toxicity.
Alleaume, AM; Bernard, BA; Commo, S; El Houari, F; Ito, S; Michard, Q; Rocchetti, J; Wakamatsu, K, 2008
)
0.59
"Microcalorimetric technique based on heat-output measurement, direct microorganism counting and enzymatic activity determination, have been explored to evaluate the toxic effects of diphenol species (catechol, resorcinol, and hydroquinone) on soil microbial activity."( Study on the toxic effects of diphenol compounds on soil microbial activity by a combination of methods.
Bramanti, E; Chen, H; Choi, MM; Wang, F; Yao, J; Zaray, G, 2009
)
0.54
"Deoxyarbutin exerts potent tyrosinase inhibition, lessened cytotoxicity, and certain antioxidation potential, may serve as an effective and safe alternative to hydroquinone for use in skin whitening."( Effects of hydroquinone and its glucoside derivatives on melanogenesis and antioxidation: Biosafety as skin whitening agents.
Ding, SF; Hu, ZM; Lei, TC; Xu, SZ; Zhou, Q, 2009
)
0.94
"Polychlorinated biphenyls (PCBs) are persistent organic pollutants that exhibit various toxic effects in animals and exposed human populations."( Cytotoxic effects of polychlorinated biphenyl hydroquinone metabolites in rat hepatocytes.
Chan, K; Feng, CY; Lehmler, HJ; O'Brien, PJ; Robertson, L; Sivagnanam, M, 2010
)
0.62
" 5 microM) for more than 15 h allows V79 cells to gain enhanced adaptability to survive exposure to high toxic HQ doses afterwards."( Potentiometric biosensor for studying hydroquinone cytotoxicity in vitro.
Chen, Q; Wang, Y; Zeng, X, 2010
)
0.63
"Although phenolic compounds are intensively studied for their toxic effects on the environment, the toxicity of catechol, resorcinol and hydroquinone mixtures are still not well understood because most previous bioassays are conducted solely using single compound based on acute tests."( Toxicity of three phenolic compounds and their mixtures on the gram-positive bacteria Bacillus subtilis in the aquatic environment.
Chen, H; Chen, K; Choi, MM; Wang, F; Yao, J; Zaray, G; Zhou, Y; Zhuang, R, 2010
)
0.56
" Thus, hydroquinone is safe at concentrations of ≤1% in hair dyes and is safe for use in nail adhesives."( Final amended safety assessment of hydroquinone as used in cosmetics.
Andersen, FA; Belsito, DV; Bergfeld, WF; Hill, RA; Klaassen, CD; Liebler, DC; Marks, JG; Shank, RC; Slaga, TJ; Snyder, PW,
)
0.86
" Cytotoxicity measurements in 15 cancer cell lines demonstrates that oxidatively activated DNA-modifying agents are highly selective, as the analogue tested has IC(50) values less than 10 μM for only three of the 15 cell lines; in contrast, cisplatin is highly toxic to 13 of the 15 cell lines."( Oxidatively activated DNA-modifying agents for selective cytotoxicity.
Bell, T; Li, G; Merino, EJ, 2011
)
0.37
" When the cytotoxic effects of arbutin and hydroquinone (HQ), a deglycosylated metabolite of arbutin, were compared, HQ was more toxic than arbutin."( Role of metabolism by the human intestinal microflora in arbutin-induced cytotoxicity in HepG2 cell cultures.
Hwang, YP; Jeong, HG; Jeong, TC; Kang, MJ; Khanal, T; Kim, DH; Kim, HG; Kong, MJ; Yeo, HK, 2011
)
0.63
" We have shown that in vivo exposure to hydroquinone (HQ), the most oxidative compound of cigarette smoke and a toxic benzene metabolite, affects circulating neutrophils, making them unresponsive to a subsequent bacterial infection."( Intracellular mechanisms of hydroquinone toxicity on endotoxin-activated neutrophils.
Bolonheis, SM; Farsky, SH; Ferreira, ZF; Hebeda, CB; Muscará, MN; Pinedo, FJ; Teixeira, SA, 2012
)
0.94
" To identify key environmental variable for the toxic action of potential quinone algicides, we tested the toxicity of hydroquinone (HQ) to different eukaryotic and prokaryotic freshwater phototrophs in terms of growth performance and investigated also the effect of HQ oxidation at different pH values on its algicidal potential."( Toxicity of hydroquinone to different freshwater phototrophs is influenced by time of exposure and pH.
Bährs, H; Putschew, A; Steinberg, CE, 2013
)
0.98
" The adverse effects of HQ on respiratory systems have been studied, but genotoxicity HQ on human lung cells is unclear."( Genotoxicity of hydroquinone in A549 cells.
Arthur, D; Lavin, MF; Lee, J; Liu, F; Ng, JC; Peng, C; Xia, Q, 2013
)
0.74
"Skin irritation is one of the most common adverse reactions in hydroquinone (HQ) and retinoic acid (RA)."( S100B as a potential biomarker for the detection of cytotoxicity of melanocytes.
Cheong, KA; Kim, CH; Lee, AY; Noh, M, 2014
)
0.64
" Adverse events were noted on every visit."( A randomized, double-blind, placebo-controlled clinical trial on the efficacy and safety of 3% Rumex occidentalis cream versus 4% hydroquinone cream in the treatment of melasma among Filipinos.
Handog, EB; Mendoza, CG; Singzon, IA, 2014
)
0.61
"Rumex occidentalis 3% cream is a safe and effective skin-lightening agent for melasma and is comparable in efficacy with 4% HQ cream."( A randomized, double-blind, placebo-controlled clinical trial on the efficacy and safety of 3% Rumex occidentalis cream versus 4% hydroquinone cream in the treatment of melasma among Filipinos.
Handog, EB; Mendoza, CG; Singzon, IA, 2014
)
0.61
"1%) reported adverse effects."( Efficacy and safety of fluocinolone acetonide, hydroquinone, and tretinoin cream in chinese patients with melasma: a randomized, double-blind, placebo-controlled, multicenter, parallel-group study.
Dang, Y; Gong, Z; Lai, W; Li, L; Liu, L; Wang, X; Yang, Q; Zhao, G; Zheng, M; Zou, Y, 2015
)
0.67
" This study aimed to examine the effect of benzene and its metabolite hydroquinone on glucose regulating organs, liver and pancreas, and to reveal the involved toxic mechanisms, in rats."( The molecular mechanisms of liver and islets of Langerhans toxicity by benzene and its metabolite hydroquinone in vivo and in vitro.
Abdollahi, M; Baeeri, M; Bahadar, H; Ghafour-Boroujerdi, E; Gholami, M; Maqbool, F; Mostafalou, S, 2015
)
0.87
"The SCCS considers the use of β-arbutin to be safe for consumers in cosmetic products in a concentration up to 7% in face creams provided that the contamination of hydroquinone in the cosmetic formulations remain below 1 ppm."( Opinion of the Scientific Committee on Consumer Safety (SCCS)--Opinion on the safety of the use of β-arbutin in cosmetic products.
Degen, GH, 2015
)
0.61
"Although on the basis of the provided scientific data the use of deoxyarbutin as such can be considered safe for consumers in cosmetic products in a concentration up to 3% in face creams, hydroquinone will be formed at levels which raise concerns with regard to the safety of such products during life-cycle of the product (e."( Opinion of the Scientific Committee on Consumer safety (SCCS) - Opinion on the safety of the use of deoxyarbutin in cosmetic products.
Degen, GH, 2016
)
0.62
"Melasma's high prevalence and profound psychological impact on patients necessitate efficacious, economical, and safe therapeutic interventions."( Comparison of the therapeutic efficacy and safety of combined oral tranexamic acid and topical hydroquinone 4% treatment vs. topical hydroquinone 4% alone in melasma: a parallel-group, assessor- and analyst-blinded, randomized controlled trial with a shor
Abedini, R; Akbari, Z; Ghayoumi, A; Goodarzi, A; Hedayat, K; Hosseini, H; Lajevardi, V, 2017
)
0.67
" Side effect occurrence was also similar, but treatment satisfaction was higher in the intervention group than the controls, with 82."( Comparison of the therapeutic efficacy and safety of combined oral tranexamic acid and topical hydroquinone 4% treatment vs. topical hydroquinone 4% alone in melasma: a parallel-group, assessor- and analyst-blinded, randomized controlled trial with a shor
Abedini, R; Akbari, Z; Ghayoumi, A; Goodarzi, A; Hedayat, K; Hosseini, H; Lajevardi, V, 2017
)
0.67
" No serious adverse events were reported."( Efficacy and safety of a novel picosecond laser using combination of 1 064 and 595 nm on patients with melasma: A prospective, randomized, multicenter, split-face, 2% hydroquinone cream-controlled clinical trial.
Choi, YJ; Kim, BJ; Kim, JY; Kim, WS; Ko, EJ; Min, JH; Nam, JH; Park, KY, 2017
)
0.65
"A 750 picosecond laser using 1 064 and 595 nm was effective and safe for the treatment of Korean melasma patients."( Efficacy and safety of a novel picosecond laser using combination of 1 064 and 595 nm on patients with melasma: A prospective, randomized, multicenter, split-face, 2% hydroquinone cream-controlled clinical trial.
Choi, YJ; Kim, BJ; Kim, JY; Kim, WS; Ko, EJ; Min, JH; Nam, JH; Park, KY, 2017
)
0.65
"The nonablative, fractional, 1,927-nm diode laser is theoretically a safe and effective treatment for hyperpigmentation and melasma in darker skin and may potentiate topical cosmeceutical delivery."( The Safety and Efficacy of Treatment With a 1,927-nm Diode Laser With and Without Topical Hydroquinone for Facial Hyperpigmentation and Melasma in Darker Skin Types.
Bolton, J; Fabi, SG; Jones, IT; Larsen, L; Vanaman Wilson, MJ, 2018
)
0.7
" No adverse events were noted."( The Safety and Efficacy of Treatment With a 1,927-nm Diode Laser With and Without Topical Hydroquinone for Facial Hyperpigmentation and Melasma in Darker Skin Types.
Bolton, J; Fabi, SG; Jones, IT; Larsen, L; Vanaman Wilson, MJ, 2018
)
0.7
"The management of melasma is still challenging, and new treatment modalities with favorable side effect profile are required."( The efficacy and safety of topical 5% methimazole vs 4% hydroquinone in the treatment of melasma: A randomized controlled trial.
Dadkhahfar, S; Gheisari, M; Moghimi, HR; Najar Nobari, N; Niknejad, N; Olamaei, E, 2020
)
0.8
" Original studies that reported pre- and post-treatment Melasma Area Severity Index (MASI)/modified Melasma Area Severity Index (mMASI) scores and/or adverse effects (AEs) were eligible for inclusion."( Efficacy and safety of topical agents in the treatment of melasma: What's evidence? A systematic review and meta-analysis.
Aljabban, A; Bain, PA; Bay, CP; Chang, YF; Chung, HJ; Desai, SR; Lee, TL; Oyerinde, O, 2023
)
0.91
" The hydroquinone 4% cohort experienced 5 adverse events, while there were no adverse events associated with the novel topical product."( A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
Bajaj, S; Bell, M; Fabi, S; Geronemus, R; Robinson, D; Wang, J; Widgerow, A, 2023
)
1.42
"A novel topical product with PATH-3 Technology, designed to counteract various steps in pigmentation pathways, has been demonstrated to be safe and effective in treating facial dyschromia."( A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
Bajaj, S; Bell, M; Fabi, S; Geronemus, R; Robinson, D; Wang, J; Widgerow, A, 2023
)
0.91
"Hydroquinone, a potent toxic agent of cigarette smoke, damages retinal pigmented epithelial cells by triggering oxidative stress and mitochondrial dysfunction, two events causally related to the development and progression of retinal diseases."( Cardiolipin-mediated temporal response to hydroquinone toxicity in human retinal pigmented epithelial cell line.
Bellezza, I; Bereshchenko, O; Cagini, C; Cellini, B; Corazzi, L; Davidescu, M; Di Michele, A; Fettucciari, K; Macchioni, L; Mezzasoma, L; Pariano, M; Pascucci, L, 2023
)
2.62

Pharmacokinetics

ExcerptReferenceRelevance
"A physiological pharmacokinetic model for benzene, incorporating metabolic transformations, is used to explore why benzene, but not phenol--its primary metabolite--is carcinogenic at many sites in rats."( Mechanisms of benzene carcinogenesis: application of a physiological model of benzene pharmacokinetics and metabolism.
Bois, FY; Smith, MT; Spear, RC, 1991
)
0.28
"A physiologically based pharmacokinetic (PBPK) model was developed to describe the disposition of benzene in 3- and 18-month C57BL/6N mice and to examine the relevant physiologic and/or biochemical parameters governing previously observed age-related changes in the disposition of benzene."( Age-related changes in benzene disposition in male C57BL/6N mice described by a physiologically based pharmacokinetic model.
Birnbaum, LS; McMahon, TF; Medinsky, MA, 1994
)
0.29
" A pharmacokinetic interaction between PH and HQ is also hypothesized to contribute to the observation."( Pharmacokinetic interaction between benzene metabolites, phenol and hydroquinone, in B6C3F1 mice.
Hoener, BA; Legathe, A; Tozer, TN, 1994
)
0.52
" An initial physiologically based pharmacokinetic model was developed to characterize the role of kinetics in the strain differences observed in HQ-induced renal toxicity and tumorigenicity."( Development of a physiologically based pharmacokinetic model for hydroquinone.
Corley, RA; English, JC; Fiorica, LA; Hill, TS; Morgott, DA, 2000
)
0.54
"This study was conducted to determine the pharmacokinetic properties of hydroquinine after oral administration in adult patients with muscle cramps."( Hydroquinine pharmacokinetics after oral administration in adult patients with muscle cramps.
Jansen, PH; Smits, P; Tuinte, C; van Kan, HJ; Verbeek, AL, 2000
)
0.31
" Hydroquinine concentrations were measured, and calculations were made of pharmacokinetic parameters using non-linear curve fitting."( Hydroquinine pharmacokinetics after oral administration in adult patients with muscle cramps.
Jansen, PH; Smits, P; Tuinte, C; van Kan, HJ; Verbeek, AL, 2000
)
0.31
" With an elimination half-life of 10."( Hydroquinine pharmacokinetics after oral administration in adult patients with muscle cramps.
Jansen, PH; Smits, P; Tuinte, C; van Kan, HJ; Verbeek, AL, 2000
)
0.31

Compound-Compound Interactions

Hydroquinone 4% cream with 2% glycolic acid is safe and effective in improving photodamage on the neck and upper chest.

ExcerptReferenceRelevance
"Hydroquinone 4% cream with 2% glycolic acid is safe and effective in improving photodamage on the neck and upper chest when used alone or in combination with salicylic acid peels."( Efficacy of hydroquinone cream (USP 4%) used alone or in combination with salicylic acid peels in improving photodamage on the neck and upper chest.
Gladstone, HB; Jeffers, M; Moy, RL; Nguyen, SL; Ottomeyer, T; Williams, R; Wortzman, M, 2000
)
2.13
" Single session IPL combined with stable fixed-dose triple combination treatment is a safe and effective treatment for refractory mixed and dermal melasma."( Single-session intense pulsed light combined with stable fixed-dose triple combination topical therapy for the treatment of refractory melasma.
Figueiredo Souza, L; Trancoso Souza, S,
)
0.13
"To observe and analyze the efficacy of tranexamic acid combined with reduced glutathione in chloasma treatment."( Clinical observation on tranexamic acid combined with reduced glutathione for the treatment of chloasma.
Feng, C; Yan, M, 2018
)
0.48
"The aim of this study was to assess the effectiveness of photo rejuvenation combined with tranexamic acid and hydroquinone cream in the treatment of complex facial pigmentation."( Efficacy of photorejuvenation combined with tranexamic acid and hydroquinone cream in the treatment of complex facial pigmentation.
Lin, C; Zhu, X, 2023
)
1.36

Bioavailability

ExcerptReferenceRelevance
" The in vivo bioavailability for 24-h application in humans was 45."( Human in vivo and in vitro hydroquinone topical bioavailability, metabolism, and disposition.
Cox, R; Hui, X; Maibach, HI; Melendres, J; Quan, D; Serranzana, S; Wester, RC; Zhai, H, 1998
)
0.6
" The bioavailability of HQ was determined by blood sampling simultaneously at arterial and venous sites beginning immediately after administration to conscious rats."( Bioavailability and metabolism of hydroquinone after intratracheal instillation in male rats.
Deisinger, PJ; English, JC, 1999
)
0.58
" (d) Our data therefore indicate superior endothelial function in the obese relative to the lean Zucker rat, reflected by a greater regulation of vasoconstrictor reactivity by basal NO, while the regulation of NO bioavailability by superoxide anion is similar."( Investigation of basal endothelial function in the obese Zucker rat in vitro.
Anggård, EE; Carrier, MJ; Laight, DW, 2000
)
0.31
" This efficient route enabled to scale up the synthesis of an orally bioavailable glycine antagonist showing outstanding in vivo anti-hyperalgesic activity in different animal models of sustained inflammation and chronic neuropathic pain."( Chiral tetrahydroquinoline derivatives as potent anti-hyperalgesic agents in animal models of sustained inflammation and chronic neuropathic pain.
Alvaro, G; Barnaby, RJ; Bertani, B; Corsi, M; Di Fabio, R; Donati, D; Gentile, G; Giacobbe, S; Pentassuglia, G; Pizzi, DM; Quartaroli, M; Ratti, E; Spada, S; Vitulli, G, 2007
)
0.34
"Phenol was investigated for the ability of TiO2 photocatalysis to increase its bioavailability as an electron donor for denitrification."( Enhanced phenol bioavailability by means of photocatalysis.
Chen, J; Rittmann, BE; Wang, J; Yan, N; Zhang, Y, 2013
)
0.39
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Quantitative and qualitative analysis of the extract and the digestive stability and bioavailability of arbutin and hydroquinone were performed by HPLC assay and simulated in vitro digestion, respectively."( Proteome changes in human bladder T24 cells induced by hydroquinone derived from Arctostaphylos uva-ursi herbal preparation.
Butorac, A; Durgo, K; Gunjača, M; Huđek Turković, A; Lovrić, M; Marjanović, M; Peraica, M; Rašić, D; Rusak, G; Šola, I; Vujčić Bok, V, 2022
)
1.18

Dosage Studied

An analytical study has been conducted on those skin bleaching products through colorimetric identifications of hydroquinone. Dose-response analyses of selected causes of death, including renal carcinoma, demonstrated no statistically significant heterogeneities.

ExcerptRelevanceReference
" No differences in survival were observed between dosed and control groups of rats or mice."( Toxicity and carcinogenicity of hydroquinone in F344/N rats and B6C3F1 mice.
Bucher, J; Eustis, SL; Haseman, JK; Huff, JE; Kari, FW, 1992
)
0.57
"6% unlabeled HQ in the diet for 2 days or were dosed by gavage with 311 mg/kg [14C]HQ."( Metabolic fate and disposition of [14C]hydroquinone given orally to Sprague-Dawley rats.
Divincenzo, GD; Hamilton, ML; Reynolds, RC; Ziegler, DA, 1984
)
0.54
" Dose-response analyses of selected causes of death, including renal carcinoma, demonstrated no statistically significant heterogeneities or linear trends according to estimated career hydroquinone exposure (mg/m3-years) or time from first exposure."( Mortality study of employees engaged in the manufacture and use of hydroquinone.
Hearne, FT; O'Donoghue, JL; Pifer, JW; Swanson, FA, 1995
)
0.72
" In four groups, rats were dosed orally with 3% hydroquinone or 3% hydroquinone in 3% lithographic developer solution."( Experimental studies on the toxicity of lithographic developer solution.
Saito, T; Takeichi, S, 1995
)
0.55
" At 6 weeks, renal cell proliferation was increased over vehicle-controls in male F344 rats dosed at 50 mg/kg."( Measurement of cell proliferation in the kidneys of Fischer 344 and Sprague-Dawley rats after gavage administration of hydroquinone.
English, JC; Moyer, C; O'Donoghue, JL; Perry, LG; Vlaovic, M, 1994
)
0.5
" Dose-response analyses of HQ, BQ, or DX inhibition of GM-CSF-induced proliferative and colony-forming responses indicated that murine GM progenitors were significantly less sensitive to HQ than to the majority of myeloid BM cells that proliferated in response to GM-CSF."( In vitro effects of hydroquinone, benzoquinone, and doxorubicin on mouse and human bone marrow cells at physiological oxygen partial pressure.
Burkart, PT; Colinas, RJ; Lawrence, DA, 1994
)
0.61
" F0 and F1 parental animals were dosed daily for at least 10 weeks prior to cohabitation, during cohabitation, and until scheduled termination."( A two-generation reproduction study with hydroquinone in rats.
Blacker, AM; English, JC; Krasavage, WJ; Murphy, SJ; Schroeder, RE; Simon, GS, 1993
)
0.55
" In general, overall similarities in the relative sensitivity of lymphoblastogenesis were obtained when the human dose-response curves were compared to the rodent response curves."( Comparative effects of immunotoxic chemicals on in vitro proliferative responses of human and rodent lymphocytes.
Lang, DS; Luster, MI; Meier, KL, 1993
)
0.29
" An analytical study has been conducted on those skin bleaching products through colorimetric identifications of hydroquinone, corticoids and mercurial derivates and the dosage of hydroquinone by High Performance Liquid Chromatography (HPLC)."( [Artificial depigmentation practice of the skin in women of Dakar and analytical study of the cosmetic products used].
Ba, D; Ciss, M; Diop, A; Diouf, A; Guisse, MB; Ndiaye, B; Niane, B; Sylla, R, 1994
)
0.5
" The procedures refer to situations when detailed comparisons make sense only if the sensitivity of the trial has been shown, for example, if a dose-response relationship or a difference between active control and placebo has been established."( Testing strategies in multi-dose experiments including active control.
Bauer, P; Hothorn, L; Maurer, W; Röhmel, J, 1998
)
0.3
" Groups of five males and five females were dosed with TBHQ, HQ, or the vehicle (hydrophilic ointment) daily (M-F) for 13 weeks."( Depigmentation with tert-butyl hydroquinone using black guinea pigs.
Juberg, DR; Maibach, HI; O'Donoghue, J; Patrick, E,
)
0.42
" KBrO3 dosed ip (12."( Hydroquinone: genotoxicity and prevention of genotoxicity following ingestion.
Aebi, J; Barber, ED; Fiorica, L; Hill, T; O'Donoghue, J,
)
1.57
" A dosing regimen for the glycolic acid formulations that was tolerated by the hairless guinea pigs and significantly decreased stratum corneum turnover time was determined using the dansyl chloride staining technique."( The effects of an alpha hydroxy acid (glycolic acid) on hairless guinea pig skin permeability.
Bronaugh, RL; Hood, HL; Kraeling, ME; Robl, MG, 1999
)
0.3
" This model represents the first stage in the development of a biologically based dose-response model for improving the scientific basis for human health risk assessments of HQ."( Development of a physiologically based pharmacokinetic model for hydroquinone.
Corley, RA; English, JC; Fiorica, LA; Hill, TS; Morgott, DA, 2000
)
0.54
" An important determinant of the sensitivity to detect small dose changes is shown to be the slope-to-intercept ratio of the dose-response curve."( Polymer gels for magnetic resonance imaging of radiation dose distributions at normal room atmosphere.
Does, MD; Fong, PM; Gore, JC; Keil, DC, 2001
)
0.31
" HQ was extensively metabolized following oral dosing with typically <3% of the dose excreted as parent compound."( Metabolism and disposition of hydroquinone in Fischer 344 rats after oral or dermal administration.
Deisinger, PJ; English, JC, 2005
)
0.62
" Also there was achieved a parallel analysis of buthylhydroxyanisol, as a preservative, and hydroquinone, as a degradation product of calcium dobesilate, present in these dosage forms."( Validation of liquid chromatographic method for analysis of lidocaine hydrochloride, dexamethasone acetate, calcium dobesilate, buthylhydroxyanisol and degradation product hydroquinone in suppositories and ointment.
Ivanovic, I; Markovic, S; Petrovic, S; Zecevic, M; Zivanovic, Lj, 2005
)
0.74
" Tremors occurred within one hour of dosing and resolved by the 6-h examination."( Hydroquinone: acute and subchronic toxicity studies with emphasis on neurobehavioral and nephrotoxic effects.
Bernard, LG; English, JC; O'Donoghue, JL; Topping, DC, 2007
)
1.78
" The rats were observed daily and body weights were taken before initial dosing and at weekly intervals thereafter."( Inhibition by dietary hydroquinone of acetylaminofluorene induction of initiation of rat liver carcinogenesis.
Duan, JD; Iatropoulos, MJ; Jeffrey, AM; Williams, GM, 2007
)
0.65
" There was no information on tobacco smoking habits and no dose-response relationship."( Hydroquinone: an evaluation of the human risks from its carcinogenic and mutagenic properties.
McGregor, D, 2007
)
1.78
"04) all had a dose-response relationship."( [Effects of hydroquinone on expression of human 8-oxo-guanine DNA glycosylase mRNA in human A549 lung adenocarcinoma cell strains].
Ke, YB; Shu, Y; Wang, L; Zhang, ZZ, 2009
)
0.73
"In all, 25 patients completing the study per protocol were treated daily for 24 weeks (cohort A); 6 patients were treated daily for 12 weeks followed by 12 weeks of maintenance therapy (cohort B); and 21 patients were treated daily for 12 weeks, relapsed during the maintenance phase, and returned to daily dosing (cohort C)."( Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma.
Bhawan, J; Colón, LE; Gottschalk, RW; Grimes, PE; Guevara, IL; Johnson, LA; Pandya, AG, 2010
)
0.36
" The concentration that reduced the viable cells by 50% (CC(50)) and the concentration that increased the viability of UV-irradiated cells to 50% (EC(50)) were determined from the dose-response curves."( Cytotoxicity of dental compounds towards human oral squamous cell carcinoma and normal oral cells.
Koh, T; Machino, M; Murakami, Y; Sakagami, H; Umemura, N,
)
0.13
" The proposed methods were checked using laboratory-prepared mixtures and were successfully applied for the analysis of pharmaceutical formulation containing the cited drugs with no interference from other dosage form additives."( Successive spectrophotometric resolution as a novel technique for the analysis of ternary mixtures of pharmaceuticals.
Fahmy, NM; Lotfy, HM; Shehata, MA; Tawakkol, SM, 2014
)
0.4
" The method was applied for the determination of the studied drugs in different dosage forms and biological fluids."( Simultaneous determination of some dihydroxybenzenesulphonic acid derivatives and their degradation product and main impurity (hydroquinone) by ion-pair liquid chromatography.
Tolba, MM, 2014
)
0.61
" To enable sensitive monitoring the dose-response characteristics of the consecutive neurobehavioral disorders, mice received gradient concentrations of hydroquinone (2%, 4%, 6%)."( Developmental Neurotoxic Effects of Percutaneous Drug Delivery: Behavior and Neurochemical Studies in C57BL/6 Mice.
Cai, M; Feng, J; Fu, M; He, Q; Huang, Q; Lv, W; Shang, J; Wu, H, 2016
)
0.63
" Based on the dose-response of γH2AX and Hill model, the ability to induce DNA double-strand break can be evaluated as acrolein>formaldehyde>acetaldehyde>benzene."( Assessment of genotoxicity of four volatile pollutants from cigarette smoke based on the in vitro γH2AX assay using high content screening.
Chen, H; Hou, H; Hu, Q; Liu, Y; Wang, A; Zhang, S, 2017
)
0.46
" dosing combination of dietary supplements for AMD patients, has been evaluated as a possible treatment and restraining option for AMD."( Regulation of oxidative stress and inflammatory responses in human retinal pigment epithelial cells.
Harju, N, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (3 Items)

ItemProcessFrequency
Mascarilla Facial de celulosacore-ingredient1
Open Beauty Factscore-ingredient1
Productos no alimenticioscore-ingredient1

Roles (7)

RoleDescription
cofactorAn organic molecule or ion (usually a metal ion) that is required by an enzyme for its activity. It may be attached either loosely (coenzyme) or tightly (prosthetic group).
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
skin lightening agentAny cosmetic used to lighten the colour of skin by reducing the concentration of melanin.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
benzenediol
hydroquinonesBenzenediols that have the hydroxy substituents in the 1- and 4-positions.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (35)

PathwayProteinsCompounds
Metabolism14961108
Biological oxidations150276
Phase I - Functionalization of compounds69175
Pyrimidine Metabolism2353
Glycerolipid Metabolism1124
Phospholipid Biosynthesis2529
Glycerol Phosphate Shuttle39
Riboflavin Metabolism515
beta-Ureidopropionase Deficiency2353
UMP Synthase Deficiency (Orotic Aciduria)2353
Dihydropyrimidinase Deficiency2353
MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy)2353
Glycerol Kinase Deficiency1124
D-Glyceric Acidura1124
Familial Lipoprotein Lipase Deficiency1124
TCA Cycle1825
L-Alanine Metabolism1016
TCA cycle (ubiquinol-2)1824
TCA cycle (ubiquinol-3)1823
TCA cycle (ubiquinol-4)1824
TCA cycle (ubiquinol-5)1823
TCA cycle (ubiquinol-6)1825
TCA cycle (ubiquinol-7)1825
TCA cycle (ubiquinol-8)1825
TCA cycle (ubiquinol-9)1823
TCA cycle (ubiquinol-10)1824
TCA cycle (ubiquinol-0)1825
Citrate Cycle1930
TCA Cycle (Ubiquinol-2)424
TCA Cycle (Ubiquinol-3)423
TCA Cycle (Ubiquinol-4)424
TCA Cycle (Ubiquinol-5)423
TCA Cycle (Ubiquinol-6)425
TCA Cycle (Ubiquinol-7)425
TCA Cycle (Ubiquinol-8)425
TCA Cycle (Ubiquinol-9)423
TCA Cycle (Ubiquinol-10)424
TCA Cycle (Ubiquinol-0)425
4-hydroxyacetophenone degradation520
4-aminophenol degradation016
4-nitrophenol degradation I916
alkylnitronates degradation350
firefly bioluminescence125
superpathway of parathion degradation08
Benzene metabolism010

Protein Targets (119)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency0.97200.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency0.97200.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency14.12540.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency35.48130.125919.1169125.8920AID2549
interleukin 8Homo sapiens (human)Potency66.82420.047349.480674.9780AID651758
endonuclease IVEscherichia coliPotency10.00000.707912.432431.6228AID1708
Nrf2Homo sapiens (human)Potency18.35640.09208.222223.1093AID624149
thioredoxin reductaseRattus norvegicus (Norway rat)Potency32.85020.100020.879379.4328AID588453
15-lipoxygenase, partialHomo sapiens (human)Potency15.84890.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency44.66840.141337.9142100.0000AID1490
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency61.26043.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency28.49800.006038.004119,952.5996AID1159521; AID1159523
ATAD5 protein, partialHomo sapiens (human)Potency20.58780.004110.890331.5287AID493107
NFKB1 protein, partialHomo sapiens (human)Potency10.00000.02827.055915.8489AID895; AID928
GLS proteinHomo sapiens (human)Potency6.86600.35487.935539.8107AID624146; AID624170
TDP1 proteinHomo sapiens (human)Potency23.35510.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency4.55450.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency7.94330.180013.557439.8107AID1468
ThrombopoietinHomo sapiens (human)Potency12.58930.02517.304831.6228AID917; AID918
AR proteinHomo sapiens (human)Potency41.43190.000221.22318,912.5098AID1259243; AID1259247; AID588516; AID743035; AID743042; AID743054; AID743063
DNA polymerase III, partialBacillus subtilisPotency5.32331.062114.152826.6795AID485295
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency35.48130.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency1.99530.00137.762544.6684AID914; AID915
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency40.27440.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency22.20770.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency64.67370.000417.946075.1148AID1346795
regulator of G-protein signaling 4Homo sapiens (human)Potency23.77810.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency4.36490.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency52.16970.000214.376460.0339AID588533; AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency22.60820.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency35.75950.000817.505159.3239AID1159527; AID588544; AID588546
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency15.64690.001530.607315,848.9004AID1224819; AID1224820; AID1224821; AID1224823; AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency26.84330.375827.485161.6524AID588526; AID588527; AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency54.15040.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency35.52880.000229.305416,493.5996AID1259244; AID588513; AID588514; AID743069; AID743075; AID743077; AID743078; AID743079
cytochrome P450 2D6Homo sapiens (human)Potency43.64860.00108.379861.1304AID1645840
ParkinHomo sapiens (human)Potency29.09290.819914.830644.6684AID720573
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency23.75300.001024.504861.6448AID588534; AID588535
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency23.10240.001019.414170.9645AID743094
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency20.28410.023723.228263.5986AID743222; AID743223
arylsulfatase AHomo sapiens (human)Potency30.13131.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency3.87550.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency29.59590.000723.06741,258.9301AID651777; AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency60.75780.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency44.52470.001628.015177.1139AID1224843; AID1224895; AID1259385
activating transcription factor 6Homo sapiens (human)Potency24.38820.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency43.369019.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency38.33850.057821.109761.2679AID1159526
Histone H2A.xCricetulus griseus (Chinese hamster)Potency45.89580.039147.5451146.8240AID1224845; AID1224896
Caspase-7Cricetulus griseus (Chinese hamster)Potency27.13950.006723.496068.5896AID1346980
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00280.540617.639296.1227AID2364; AID2528
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency91.99970.01262.451825.0177AID485313
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency21.331323.934123.934123.9341AID1967
hemoglobin subunit betaHomo sapiens (human)Potency26.20000.31629.086131.6228AID910; AID925
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency7.85560.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency56.23410.006026.168889.1251AID488953
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency39.81070.010039.53711,122.0200AID588547
caspase-3Cricetulus griseus (Chinese hamster)Potency27.13950.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency32.59250.000323.4451159.6830AID743065; AID743066; AID743067
heat shock protein beta-1Homo sapiens (human)Potency17.26550.042027.378961.6448AID743210
flap endonuclease 1Homo sapiens (human)Potency3.76860.133725.412989.1251AID588795
ras-related protein Rab-9AHomo sapiens (human)Potency58.04790.00022.621531.4954AID485297
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency17.55310.00378.618923.2809AID2660; AID2666; AID2668
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency7.31350.000627.21521,122.0200AID651741; AID720636; AID743202; AID743219
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency8.49210.425612.059128.1838AID504536
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency19.46860.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency15.92710.004611.374133.4983AID463097; AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency11.99540.005612.367736.1254AID624032; AID624044
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency1.00000.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency89.12510.177824.735279.4328AID488949
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency19.95260.00106.000935.4813AID944
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency7.32730.891312.067628.1838AID1459; AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency30.45100.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency36.87940.002319.595674.0614AID651631; AID720552
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency30.45100.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Nuclear receptor ROR-gammaHomo sapiens (human)Potency10.59090.026622.448266.8242AID651802
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency54.15040.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency46.98050.011912.222168.7989AID588378; AID651632
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency10.69100.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Carbonic anhydrase 2Homo sapiens (human)Ki0.09000.09003.89507.7000AID977610
Chain A, Carbonic anhydrase 2Homo sapiens (human)Ki0.09000.09003.89507.7000AID977610
Chain A, Carbonic anhydrase 2Homo sapiens (human)Ki0.09000.09003.89507.7000AID977610
AcetylcholinesteraseElectrophorus electricus (electric eel)Ki0.00120.00121.25638.9000AID1292256
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)1,477.96920.03403.987110.0000AID1799717; AID305160; AID331282; AID336442; AID395015; AID400520; AID405958; AID467606; AID493982; AID662538; AID687639; AID687640
Carbonic anhydrase 12Homo sapiens (human)Ki116.94930.00021.10439.9000AID1798641; AID342484
Carbonic anhydrase 1Homo sapiens (human)Ki115.61000.00001.372610.0000AID1798641; AID1803139; AID331291; AID342475
Carbonic anhydrase 2Homo sapiens (human)Ki114.49320.00000.72369.9200AID1798641; AID1803139; AID331292; AID342476
Carbonic anhydrase 3Homo sapiens (human)Ki116.97790.00022.010210.0000AID1798641; AID342477
TyrosinaseMus musculus (house mouse)IC50 (µMol)137.88500.03002.21045.2300AID1799717
TyrosinaseHomo sapiens (human)IC50 (µMol)4,400.00000.02304.459310.0000AID1611943; AID1717717
Prolyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)Ki14,000.00005.00007.66679.0000AID1799825
Carbonic anhydrase 4Homo sapiens (human)Ki121.44390.00021.97209.9200AID1798641; AID1803139; AID342478
Carbonic anhydrase 6Homo sapiens (human)Ki149.78830.00011.47109.9200AID1798641; AID1803139; AID342481
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)Ki117.39930.00001.27259.9000AID1798641; AID342479
Carbonic anhydrase 7Homo sapiens (human)Ki179.46360.00021.37379.9000AID1798641; AID342482
Carbonic anhydrase 9Homo sapiens (human)Ki118.71360.00010.78749.9000AID1798641; AID342483
Carbonic anhydraseDicentrarchus labrax (European seabass)Ki5.93002.13005.53339.4100AID607497
Carbonic anhydrase 15Mus musculus (house mouse)Ki10.60000.00091.884610.0000AID331293
Carbonic anhydrase 13Mus musculus (house mouse)Ki121.69930.00021.39749.9000AID1798641; AID342486
Carbonic anhydrase 14Homo sapiens (human)Ki119.39210.00021.50999.9000AID1798641; AID342485
Carbonic anhydrase 5B, mitochondrialHomo sapiens (human)Ki117.28500.00001.34129.9700AID1798641; AID342480
large T antigenBetapolyomavirus macacaeIC50 (µMol)7.76000.160024.9724100.0000AID1903
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (182)

Processvia Protein(s)Taxonomy
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
response to bacteriumCarbonic anhydrase 3Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 3Homo sapiens (human)
melanin biosynthetic process from tyrosineTyrosinaseHomo sapiens (human)
eye pigment biosynthetic processTyrosinaseHomo sapiens (human)
visual perceptionTyrosinaseHomo sapiens (human)
cell population proliferationTyrosinaseHomo sapiens (human)
response to UVTyrosinaseHomo sapiens (human)
response to blue lightTyrosinaseHomo sapiens (human)
response to vitamin DTyrosinaseHomo sapiens (human)
melanin biosynthetic processTyrosinaseHomo sapiens (human)
thymus developmentTyrosinaseHomo sapiens (human)
response to cAMPTyrosinaseHomo sapiens (human)
pigmentationTyrosinaseHomo sapiens (human)
peptidyl-proline hydroxylation to 4-hydroxy-L-prolineProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 7Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 7Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 7Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 7Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 7Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 7Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 14Homo sapiens (human)
response to bacteriumCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (54)

Processvia Protein(s)Taxonomy
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 3Homo sapiens (human)
protein bindingCarbonic anhydrase 3Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 3Homo sapiens (human)
nickel cation bindingCarbonic anhydrase 3Homo sapiens (human)
tyrosinase activityTyrosinaseHomo sapiens (human)
copper ion bindingTyrosinaseHomo sapiens (human)
protein bindingTyrosinaseHomo sapiens (human)
identical protein bindingTyrosinaseHomo sapiens (human)
protein homodimerization activityTyrosinaseHomo sapiens (human)
procollagen-proline 4-dioxygenase activityProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
iron ion bindingProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
L-ascorbic acid bindingProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 7Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (48)

Processvia Protein(s)Taxonomy
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytoplasmCarbonic anhydrase 3Homo sapiens (human)
cytoplasmTyrosinaseHomo sapiens (human)
lysosomeTyrosinaseHomo sapiens (human)
Golgi-associated vesicleTyrosinaseHomo sapiens (human)
melanosome membraneTyrosinaseHomo sapiens (human)
melanosomeTyrosinaseHomo sapiens (human)
intracellular membrane-bounded organelleTyrosinaseHomo sapiens (human)
perinuclear region of cytoplasmTyrosinaseHomo sapiens (human)
endoplasmic reticulum lumenProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
endoplasmic reticulumProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
extracellular regionCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
cytosolCarbonic anhydrase 6Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytosolCarbonic anhydrase 7Homo sapiens (human)
cytoplasmCarbonic anhydrase 7Homo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
membraneCarbonic anhydrase 14Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 14Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 14Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (323)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1366528Cytotoxicity against wild type zebrafish embryo melanocytes assessed as change in morphology at >= 10 ug/ml treated for 72 hrs post fertilization starting from 6 to 24 hrs post fertilization2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID342483Inhibition of human carbonic anhydrase 9 catalytic domain by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID403616Antimicrobial activity against Bacillus subtilis at 30 ug/disk1997Journal of natural products, Jun, Volume: 60, Issue:6
Antimicrobial and cytotoxic phenolic glycoside esters from the New Zealand tree Toronia toru.
AID1366370Toxicity in wild type zebrafish embryos assessed as teratogenic embryo at 6.25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366467Toxicity in wild type zebrafish embryos assessed as heart beat at 5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366346Cytotoxicity against wild type zebrafish embryo melanocytes assessed as barely visible cells at 12.5 ug/ml treated for 72 hrs post fertilization starting from 6 to 24 hrs post fertilization2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366479Toxicity in wild type zebrafish embryos assessed as blood circulation at 10 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID403903Cytotoxicity against african green monkey BSC1 cells at 60 ug/disk1997Journal of natural products, Jun, Volume: 60, Issue:6
Antimicrobial and cytotoxic phenolic glycoside esters from the New Zealand tree Toronia toru.
AID607497Inhibition of Dicentrarchus labrax CA using 4-nitrophenylacetate substrate by esterase assay2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
In vitro inhibition of α-carbonic anhydrase isozymes by some phenolic compounds.
AID1366461Toxicity in wild type zebrafish embryos assessed as yolk edema at 6.25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID342477Inhibition of human carbonic anhydrase 3 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID1366347Cytotoxicity against wild type zebrafish embryo melanocytes assessed as punctate cells at 12.5 ug/ml treated for 72 hrs post fertilization starting from 6 to 24 hrs post fertilization2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID602813Inhibition of Sarcoplasmic/endoplasmic reticulum calcium ATPase in rabbit hind leg tissue microsomes assessed as rate of NADH oxidation coupled to SERCA-catalyzed ATP hydrolysis at <100 uM by spectroscopic assay2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Discovery of novel SERCA inhibitors by virtual screening of a large compound library.
AID1366376Toxicity in wild type zebrafish embryos assessed as normal embryo at 5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366383Toxicity in wild type zebrafish embryos assessed as normal embryo at 6.25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366441Toxicity in wild type zebrafish embryos assessed as pericardial edema at 5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1291716Lipophilicity, log P of compound2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1366489Toxicity in wild type zebrafish embryos assessed as unhatched embryo at 25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID687640Inhibition of mushroom tyrosinase using as L-DOPA substrate after 2 mins by spectrophotometric analysis2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
Tyrosinase inhibitory activity of a 6-isoprenoid-substituted flavanone isolated from Dalea elegans.
AID1225511Cytotoxicity against human A549 cells after 48 hrs by MTT assay2015Journal of natural products, Apr-24, Volume: 78, Issue:4
Bioactive Metabolites from the Fruits of Psoralea corylifolia.
AID1366421Toxicity in wild type zebrafish embryos assessed as eyes at 12.5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID23253Partition coefficient (logP) (carbon tetrachloride)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1366447Toxicity in wild type zebrafish embryos assessed as pericardial edema at 12.5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1611943Inhibition of human tyrosinase2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Inhibitors of Melanogenesis: An Updated Review.
AID288184Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID1366386Toxicity in wild type zebrafish embryos assessed as growth retardation at 20 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID342478Inhibition of human carbonic anhydrase 4 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID1366527Cytotoxicity against wild type zebrafish embryo melanocytes assessed as size of melanocyte at >= 10 ug/ml treated for 72 hrs post fertilization starting from 6 to 24 hrs post fertilization2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1291722Protective activity against Daboia russellii venom-induced hemorrhage in Swiss albino mouse at 100 mmol, iv assessed as hemorhagic lesion administered immediately after venom injection measured after 24 hrs relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID338272Antimicrobial activity against Pseudomonas aeruginosa DSM 1117 after 18 hrs by twofold serial dilution method1994Journal of natural products, Dec, Volume: 57, Issue:12
Biological effects of prenylated hydroquinones: structure-activity relationship studies in antimicrobial, brine shrimp, and fish lethality assays.
AID342486Inhibition of mouse carbonic anhydrase 13 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID1366332Toxicity in wild type zebrafish embryos assessed as dead embryo at 25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID23256Partition coefficient (logP) (hexane)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1291719Protective activity against Naja kaouthia venom-induced mortality in Swiss albino mouse at 100 mmol, iv by measuring venom LD50 administered immediately after venom injection measured after 24 hrs (Rvb = 2.82 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID23251Partition coefficient (logP)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID23255Partition coefficient (logP) (ether)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1366506Toxicity in wild type zebrafish embryos assessed as head malformation at 5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366363Toxicity in wild type zebrafish embryos assessed as teratogenic embryo at 5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID349297Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 assessed as bacterial growth at 3.9 ug/ml after 4 hrs by XTT assay relative to control2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
Effects of 3-(4'-geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid and its ester derivatives on biofilm formation by two oral pathogens, Porphyromonas gingivalis and Streptococcus mutans.
AID288185Permeability coefficient through artificial membrane in presence of stirred water layer2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID1366466Toxicity in wild type zebrafish embryos assessed as heart beat at 10 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID403614Antimicrobial activity against Bacillus subtilis at 120 ug/disk1997Journal of natural products, Jun, Volume: 60, Issue:6
Antimicrobial and cytotoxic phenolic glycoside esters from the New Zealand tree Toronia toru.
AID403620Antimicrobial activity against Escherichia coli at 30 ug/disk1997Journal of natural products, Jun, Volume: 60, Issue:6
Antimicrobial and cytotoxic phenolic glycoside esters from the New Zealand tree Toronia toru.
AID493982Inhibition of mushroom tyrosinase2010Bioorganic & medicinal chemistry letters, Aug-15, Volume: 20, Issue:16
A newly synthesized, potent tyrosinase inhibitor: 5-(6-hydroxy-2-naphthyl)-1,2,3-benzenetriol.
AID1717717Inhibition of human His-tagged tyrosinase expressed in HEK 293 cells using L-DOPA as substrate by MBTH based assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Advances in the Design of Genuine Human Tyrosinase Inhibitors for Targeting Melanogenesis and Related Pigmentations.
AID1366453Toxicity in wild type zebrafish embryos assessed as yolk edema at 10 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366328Anti-melanogenic activity in wild type zebrafish 24 hrs post fertilization embryos assessed as decrease in body pigmentation at 5 to 25 ug/ml after 48 hrs2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID714146Ratio of kcat to Km for Trametes versicolor laccase2012Bioorganic & medicinal chemistry, Mar-01, Volume: 20, Issue:5
Redox potentials, laccase oxidation, and antilarval activities of substituted phenols.
AID403615Antimicrobial activity against Bacillus subtilis at 60 ug/disk1997Journal of natural products, Jun, Volume: 60, Issue:6
Antimicrobial and cytotoxic phenolic glycoside esters from the New Zealand tree Toronia toru.
AID1202490Selectivity ratio of IC50 for mouse J774 cells to IC50 for epimastigote stage of Trypanosoma cruzi CL-B52015European journal of medicinal chemistry, , Volume: 96Bond-based bilinear indices for computational discovery of novel trypanosomicidal drug-like compounds through virtual screening.
AID1366371Toxicity in wild type zebrafish embryos assessed as normal embryo at 50 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366425Toxicity in wild type zebrafish embryos assessed as otoliths at 20 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID403626Antimicrobial activity against Trichophyton mentagrophytes at 120 ug/disk1997Journal of natural products, Jun, Volume: 60, Issue:6
Antimicrobial and cytotoxic phenolic glycoside esters from the New Zealand tree Toronia toru.
AID349292Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 assessed as bacterial growth at 125 ug/ml after 4 hrs by XTT assay relative to control2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
Effects of 3-(4'-geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid and its ester derivatives on biofilm formation by two oral pathogens, Porphyromonas gingivalis and Streptococcus mutans.
AID400520Inhibition of mushroom tyrosinase by spectrophotometry2004Journal of natural products, Mar, Volume: 67, Issue:3
Antityrosinase principles and constituents of the petals of Crocus sativus.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1571459Antiproliferative activity against human U87MG cells after 72 hrs by sulforhodamine B assay2018MedChemComm, Nov-01, Volume: 9, Issue:11
Towards identifying potent new hits for glioblastoma.
AID349294Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 assessed as bacterial growth at 31.2 ug/ml after 4 hrs by XTT assay relative to control2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
Effects of 3-(4'-geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid and its ester derivatives on biofilm formation by two oral pathogens, Porphyromonas gingivalis and Streptococcus mutans.
AID1366331Toxicity in wild type zebrafish embryos assessed as dead embryo at 50 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID467606Inhibition of mushroom tyrosinase after 10 mins by spectrophotometry2009Journal of natural products, Jun, Volume: 72, Issue:6
Tyrosinase-inhibitory constituents from the twigs of Cinnamomum cassia.
AID305160Inhibition of mushroom tyrosinase2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Syntheses of hydroxy substituted 2-phenyl-naphthalenes as inhibitors of tyrosinase.
AID1366358Toxicity in wild type zebrafish embryos assessed as teratogenic embryo at 50 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID349303Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 assessed as reduction of biofilm formation at 3.9 ug/ml after 48 hrs2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
Effects of 3-(4'-geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid and its ester derivatives on biofilm formation by two oral pathogens, Porphyromonas gingivalis and Streptococcus mutans.
AID1571461Antiproliferative activity against human IN1472 cells after 72 hrs by sulforhodamine B assay2018MedChemComm, Nov-01, Volume: 9, Issue:11
Towards identifying potent new hits for glioblastoma.
AID624610Specific activity of expressed human recombinant UGT1A72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1717720Inhibition of mushroom tyrosinase using L-DOPA and L-tyrosine as substrate by spectrophotometric method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Advances in the Design of Genuine Human Tyrosinase Inhibitors for Targeting Melanogenesis and Related Pigmentations.
AID1713540Inhibition of monophenolase activity of mushroom tyrosinase using L-DOPA substrate2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
ArgTX-636, a polyamine isolated from spider venom: A novel class of melanogenesis inhibitors.
AID282835Cytotoxicity against mouse L1210 cells2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID1366437Toxicity in wild type zebrafish embryos assessed as pericardial edema at 25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366519Toxicity in wild type zebrafish embryos assessed as skeletal deformities at 5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1813173Inhibition of mushroom tyrosinase2021European journal of medicinal chemistry, Dec-15, Volume: 226Design, synthesis and biological evaluation of tyrosinase-targeting PROTACs.
AID1366411Toxicity in wild type zebrafish embryos assessed as eyes at 25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1268779Cytotoxicity against human HF16 cells assessed as decrease in cell viability at 200 uM after 24 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Regulatory effect of hydroquinone-tetraethylene glycol conjugates on zebrafish pigmentation.
AID1366486Toxicity in wild type zebrafish embryos assessed as blood circulation at 12.5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID342481Inhibition of human carbonic anhydrase 6 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID403624Antimicrobial activity against Pseudomonas aeruginosa at 30 ug/disk1997Journal of natural products, Jun, Volume: 60, Issue:6
Antimicrobial and cytotoxic phenolic glycoside esters from the New Zealand tree Toronia toru.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1291715Protective activity against Daboia russellii venom-induced hemorrhage in intradermally dosed Swiss albino mouse at 100 mmol assessed as hemorhagic lesion preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs relative t2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1366402Toxicity in wild type zebrafish embryos assessed as notochord at 5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID349295Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 assessed as bacterial growth at 15.6 ug/ml after 4 hrs by XTT assay relative to control2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
Effects of 3-(4'-geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid and its ester derivatives on biofilm formation by two oral pathogens, Porphyromonas gingivalis and Streptococcus mutans.
AID309363Antiinflammatory activity in CD1 mouse assessed as inhibition of croton oil-induced ear oedema at 0.3 umol/cm^2 after 6 hrs2007Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20
Synthesis and anti-inflammatory activity of 3-(4'-geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid and its ester derivatives.
AID1571460Antiproliferative activity against human U251MG cells after 72 hrs by sulforhodamine B assay2018MedChemComm, Nov-01, Volume: 9, Issue:11
Towards identifying potent new hits for glioblastoma.
AID1202488Trypanosomicidal activity against epimastigote stage of Trypanosoma cruzi CL-B5 after 72 hrs by beta-galactosidase reporter gene assay2015European journal of medicinal chemistry, , Volume: 96Bond-based bilinear indices for computational discovery of novel trypanosomicidal drug-like compounds through virtual screening.
AID331282Inhibition of mushroom tyrosinase2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Analogues of N-hydroxy-N'-phenylthiourea and N-hydroxy-N'-phenylurea as inhibitors of tyrosinase and melanin formation.
AID349300Antimicrobial activity against Streptococcus mutans ATCC 25175 assessed as inhibition of biofilm formation at 31.3 ug/ml after 48 hrs2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
Effects of 3-(4'-geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid and its ester derivatives on biofilm formation by two oral pathogens, Porphyromonas gingivalis and Streptococcus mutans.
AID1366505Toxicity in wild type zebrafish embryos assessed as head malformation at 10 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID421667Inhibition of melanin synthesis in NHEM cells assessed as [14C]thiouracil incorporation after 72 hrs by liquid scintillation counting2009Journal of natural products, Feb-27, Volume: 72, Issue:2
Melanin synthesis inhibitors from Lespedeza floribunda.
AID1366396Toxicity in wild type zebrafish embryos assessed as growth retardation at 6.25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1292256Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 10 mins followed by substrate addition by Lineweaver-Burk plot analysis2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Acetylcholinesterase and carbonic anhydrase inhibitory properties of novel urea and sulfamide derivatives incorporating dopaminergic 2-aminotetralin scaffolds.
AID1366372Toxicity in wild type zebrafish embryos assessed as normal embryo at 25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID349291Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 assessed as bacterial growth at 250 ug/ml after 4 hrs by XTT assay relative to control2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
Effects of 3-(4'-geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid and its ester derivatives on biofilm formation by two oral pathogens, Porphyromonas gingivalis and Streptococcus mutans.
AID1366373Toxicity in wild type zebrafish embryos assessed as normal embryo at 20 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1616110Inhibition of F1F0-ATP synthase in Escherichia coli relative to control2019European journal of medicinal chemistry, Nov-15, Volume: 182Recent advancements in mechanistic studies and structure activity relationship of F
AID1366389Toxicity in wild type zebrafish embryos assessed as growth retardation at 5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366450Toxicity in wild type zebrafish embryos assessed as yolk edema at 25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID338274Toxicity against Gambusia affinis1994Journal of natural products, Dec, Volume: 57, Issue:12
Biological effects of prenylated hydroquinones: structure-activity relationship studies in antimicrobial, brine shrimp, and fish lethality assays.
AID342482Inhibition of human carbonic anhydrase 7 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID336442Inhibition of mushroom tyrosinase2002Journal of natural products, Oct, Volume: 65, Issue:10
Constituents of the stigmas of Crocus sativus and their tyrosinase inhibitory activity.
AID1225512Cytotoxicity against human K562 cells after 48 hrs by MTT assay2015Journal of natural products, Apr-24, Volume: 78, Issue:4
Bioactive Metabolites from the Fruits of Psoralea corylifolia.
AID1366440Toxicity in wild type zebrafish embryos assessed as pericardial edema at 10 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID288192Partition coefficient, log P of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1366476Toxicity in wild type zebrafish embryos assessed as blood circulation at 25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366493Toxicity in wild type zebrafish embryos assessed as unhatched embryo at 5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID403619Antimicrobial activity against Escherichia coli at 60 ug/disk1997Journal of natural products, Jun, Volume: 60, Issue:6
Antimicrobial and cytotoxic phenolic glycoside esters from the New Zealand tree Toronia toru.
AID1366534Anti-melanogenic activity in mpx:GFP transgenic zebrafish 24 hrs post fertilization embryo neutrophils assessed as decrease in pigmentation at 5 ug/ml2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID288191Membrane retention in permeability experiment with artificial membrane2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID1366342Toxicity in wild type zebrafish embryos assessed as dead embryo at 12.5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366412Toxicity in wild type zebrafish embryos assessed as eyes at 20 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1312214Substrate activity at mushroom tyrosinase assessed as Kcat for monophenolase activity in presence H2O2 by spectrophotometry based Michaelis-Menten plot analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Characterization of the action of tyrosinase on resorcinols.
AID1366512Toxicity in wild type zebrafish embryos assessed as head malformation at 12.5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID338268Antimicrobial activity against Bacillus subtilis DSM 347 after 18 hrs by twofold serial dilution method1994Journal of natural products, Dec, Volume: 57, Issue:12
Biological effects of prenylated hydroquinones: structure-activity relationship studies in antimicrobial, brine shrimp, and fish lethality assays.
AID1366525Toxicity in wild type zebrafish embryos assessed as skeletal deformities at 12.5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366414Toxicity in wild type zebrafish embryos assessed as eyes at 10 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID23252Partition coefficient (logP) (benzene)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID349301Antimicrobial activity against Streptococcus mutans ATCC 25175 assessed as effect on bacterial growth after 4 hrs by XTT assay relative to control2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
Effects of 3-(4'-geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid and its ester derivatives on biofilm formation by two oral pathogens, Porphyromonas gingivalis and Streptococcus mutans.
AID342485Inhibition of human carbonic anhydrase 14 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID1366513Toxicity in wild type zebrafish embryos assessed as head malformation at 6.25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366434Toxicity in wild type zebrafish embryos assessed as otoliths at 12.5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1291717Protective activity against Daboia russellii venom-induced mortality in Swiss albino mouse at 100 mmol, iv by measuring venom LD50 administered immediately after venom injection measured after 24 hrs (Rvb = 2.28ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1366352Cytotoxicity against wild type zebrafish embryo melanocytes assessed as change in morphology2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366500Toxicity in wild type zebrafish embryos assessed as unhatched embryo at 6.25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID398961Cytotoxicity against mouse P388 cells
AID662541Cytotoxicity against mouse Melan-a cells after 4 days by crystal voilet method2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Depigmenting activities of kojic acid derivatives without tyrosinase inhibitory activities.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1366533Cytotoxicity against mpx:GFP transgenic zebrafish 24 hrs post fertilization embryo neutrophils assessed as loss in neutrophil at 5 ug/ml relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID403899Antimicrobial activity against Trichophyton mentagrophytes at 60 ug/disk1997Journal of natural products, Jun, Volume: 60, Issue:6
Antimicrobial and cytotoxic phenolic glycoside esters from the New Zealand tree Toronia toru.
AID714147Activity of Trametes versicolor laccase by spectrophotometric analysis2012Bioorganic & medicinal chemistry, Mar-01, Volume: 20, Issue:5
Redox potentials, laccase oxidation, and antilarval activities of substituted phenols.
AID1366463Toxicity in wild type zebrafish embryos assessed as heart beat at 25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366480Toxicity in wild type zebrafish embryos assessed as blood circulation at 5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366344Cytotoxicity against wild type zebrafish embryo melanocytes assessed as number of melanocyte at >= 10 ug/ml treated for 72 hrs post fertilization starting from 6 to 24 hrs post fertilization2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366492Toxicity in wild type zebrafish embryos assessed as unhatched embryo at 10 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1366335Toxicity in wild type zebrafish embryos assessed as dead embryo at 10 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366362Toxicity in wild type zebrafish embryos assessed as teratogenic embryo at 10 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366336Toxicity in wild type zebrafish embryos assessed as dead embryo at 5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID342476Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID1366473Toxicity in wild type zebrafish embryos assessed as heart beat at 12.5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366398Toxicity in wild type zebrafish embryos assessed as notochord at 25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366375Toxicity in wild type zebrafish embryos assessed as normal embryo at 10 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID395015Inhibition of mushroom tyrosinase activity after 20 mins2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
Studies on depigmenting activities of dihydroxyl benzamide derivatives containing adamantane moiety.
AID1202489Cytotoxicity against mouse J774 cells assessed as cell viability after 48 hrs by resazurin assay2015European journal of medicinal chemistry, , Volume: 96Bond-based bilinear indices for computational discovery of novel trypanosomicidal drug-like compounds through virtual screening.
AID662542Ratio of IC50 for cytotoxicity against mouse Melan-a cells to IC50 for depigmentation in mouse Melan-a cells2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Depigmenting activities of kojic acid derivatives without tyrosinase inhibitory activities.
AID1366369Toxicity in wild type zebrafish embryos assessed as teratogenic embryo at 12.5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1571463Antiproliferative activity against human IN1760 cells after 72 hrs by sulforhodamine B assay2018MedChemComm, Nov-01, Volume: 9, Issue:11
Towards identifying potent new hits for glioblastoma.
AID1449741Selectivity ratio of Ki for recombinant human carbonic anhydrase 1 to Ki for recombinant Malassezia globosa beta-carbonic anhydrase2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Inhibition of Malassezia globosa carbonic anhydrase with phenols.
AID1366408Toxicity in wild type zebrafish embryos assessed as notochord at 12.5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366451Toxicity in wild type zebrafish embryos assessed as yolk edema at 20 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID1366487Toxicity in wild type zebrafish embryos assessed as blood circulation at 6.25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366464Toxicity in wild type zebrafish embryos assessed as heart beat at 20 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID403900Antimicrobial activity against Trichophyton mentagrophytes at 30 ug/disk1997Journal of natural products, Jun, Volume: 60, Issue:6
Antimicrobial and cytotoxic phenolic glycoside esters from the New Zealand tree Toronia toru.
AID687639Inhibition of mushroom tyrosinase using as L-tyrosine substrate after 10 mins by spectrophotometric analysis2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
Tyrosinase inhibitory activity of a 6-isoprenoid-substituted flavanone isolated from Dalea elegans.
AID403906Cytotoxicity against mouse P388 cells1997Journal of natural products, Jun, Volume: 60, Issue:6
Antimicrobial and cytotoxic phenolic glycoside esters from the New Zealand tree Toronia toru.
AID1366474Toxicity in wild type zebrafish embryos assessed as heart beat at 6.25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID761678Inhibition of mushroom tyrosinase using L-tyrosine as substrate at 23 uM after 30 mins by spectrophotometric analysis2013European journal of medicinal chemistry, Aug, Volume: 66A novel one-pot synthesis and preliminary biological activity evaluation of cis-restricted polyhydroxy stilbenes incorporating protocatechuic acid and cinnamic acid fragments.
AID338270Antimicrobial activity against Candida albicans DSM 1665 after 18 hrs by twofold serial dilution method1994Journal of natural products, Dec, Volume: 57, Issue:12
Biological effects of prenylated hydroquinones: structure-activity relationship studies in antimicrobial, brine shrimp, and fish lethality assays.
AID1366333Toxicity in wild type zebrafish embryos assessed as dead embryo at 20 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID478727Reduction of pigmentation in UV-induced hyperpigmentation brown guinea pig model at 2% applied topically bid for 4 weeks2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Evaluation of anti-pigmentary effect of synthetic sulfonylamino chalcone.
AID1366529Anti-melanogenic activity in wild type zebrafish embryo melanocytes assessed as decrease in pigmentation at <10 ug/ml treated for 72 hrs post fertilization starting from 6 to 24 hrs post fertilization2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366490Toxicity in wild type zebrafish embryos assessed as unhatched embryo at 20 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID331292Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols.
AID338269Antimicrobial activity against Micrococcus luteus DSM 348 after 18 hrs by twofold serial dilution method1994Journal of natural products, Dec, Volume: 57, Issue:12
Biological effects of prenylated hydroquinones: structure-activity relationship studies in antimicrobial, brine shrimp, and fish lethality assays.
AID403622Antimicrobial activity against Pseudomonas aeruginosa at 120 ug/disk1997Journal of natural products, Jun, Volume: 60, Issue:6
Antimicrobial and cytotoxic phenolic glycoside esters from the New Zealand tree Toronia toru.
AID1291712Protective activity against Naja kaouthia venom-induced mortality in Swiss albino mouse at 100 mmol, iv by measuring venom LD50 preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs (Rvb = 2.82 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1366415Toxicity in wild type zebrafish embryos assessed as eyes at 5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID497310Inhibition of tyrosinase2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Identification of a potent and noncytotoxic inhibitor of melanin production.
AID405958Inhibition of mushroom tyrosinase activity after 10 mins2008Journal of natural products, Jun, Volume: 71, Issue:6
Pyronane monoterpenoids from the fruit of Gardenia jasminoides.
AID342484Inhibition of human carbonic anhydrase 12 catalytic domain by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID331293Inhibition of mouse recombinant carbonic anhydrase 15 by stopped-flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols.
AID1268781Depigmentation effect on zebrafish assessed as eye color change from black to gray at 100 uM incubated for 63 hrs post fertilization by microscopic analysis2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Regulatory effect of hydroquinone-tetraethylene glycol conjugates on zebrafish pigmentation.
AID1366454Toxicity in wild type zebrafish embryos assessed as yolk edema at 5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1291710Protective activity against Daboia russellii venom-induced mortality by measuring venom LD50 in Swiss albino mouse at 100 mmol, iv preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs (Rvb = 2.28 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1366360Toxicity in wild type zebrafish embryos assessed as teratogenic embryo at 20 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366359Toxicity in wild type zebrafish embryos assessed as teratogenic embryo at 25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366424Toxicity in wild type zebrafish embryos assessed as otoliths at 25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID342480Inhibition of human carbonic anhydrase 5B by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID342479Inhibition of human carbonic anhydrase 5A by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID603955In-vivo blood to lung partition coefficients of the compound, logP(lung) in rat2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID1366530Cytotoxicity against mpx:GFP transgenic zebrafish 24 hrs post fertilization embryo neutrophils assessed as loss in neutrophil at 25 ug/ml relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1366499Toxicity in wild type zebrafish embryos assessed as unhatched embryo at 12.5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1291714Protective activity against Daboia russellii venom-induced hemorrhage in intradermally dosed Swiss albino mouse at 100 mmol assessed as hemorhagic lesion by measuring minimal hemolytic dose preincubated with venom for 1 hr followed by administration to mo2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID23254Partition coefficient (logP) (chloroform)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID403902Cytotoxicity against african green monkey BSC1 cells at 120 ug/disk1997Journal of natural products, Jun, Volume: 60, Issue:6
Antimicrobial and cytotoxic phenolic glycoside esters from the New Zealand tree Toronia toru.
AID1366409Toxicity in wild type zebrafish embryos assessed as notochord at 6.25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID349293Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 assessed as bacterial growth at 62.5 ug/ml after 4 hrs by XTT assay relative to control2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
Effects of 3-(4'-geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid and its ester derivatives on biofilm formation by two oral pathogens, Porphyromonas gingivalis and Streptococcus mutans.
AID1571462Antiproliferative activity against human IN1528 cells after 72 hrs by sulforhodamine B assay2018MedChemComm, Nov-01, Volume: 9, Issue:11
Towards identifying potent new hits for glioblastoma.
AID349296Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 assessed as bacterial growth at 7.8 ug/ml after 4 hrs by XTT assay relative to control2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
Effects of 3-(4'-geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid and its ester derivatives on biofilm formation by two oral pathogens, Porphyromonas gingivalis and Streptococcus mutans.
AID282833Activity against caspase-mediated apoptosis in mouse L1210 cells at 0.1 mM2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID1268786Photostability of compound after 18 hrs under UV irradition condition2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Regulatory effect of hydroquinone-tetraethylene glycol conjugates on zebrafish pigmentation.
AID403623Antimicrobial activity against Pseudomonas aeruginosa at 60 ug/disk1997Journal of natural products, Jun, Volume: 60, Issue:6
Antimicrobial and cytotoxic phenolic glycoside esters from the New Zealand tree Toronia toru.
AID1366330Anti-melanogenic activity in wild type zebrafish 24 hrs post fertilization embryos assessed as decrease in body pigmentation after 48 hrs2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366448Toxicity in wild type zebrafish embryos assessed as pericardial edema at 6.25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID395016Inhibition of melanin formation in C57BL/6J mouse Melan-a cells2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
Studies on depigmenting activities of dihydroxyl benzamide derivatives containing adamantane moiety.
AID1268788Drug degradation of compound assessed as Cu2+-mediated oxidation2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Regulatory effect of hydroquinone-tetraethylene glycol conjugates on zebrafish pigmentation.
AID1366395Toxicity in wild type zebrafish embryos assessed as growth retardation at 12.5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1449742Selectivity ratio of Ki for recombinant human carbonic anhydrase 2 to Ki for recombinant Malassezia globosa beta-carbonic anhydrase2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Inhibition of Malassezia globosa carbonic anhydrase with phenols.
AID1225513Increase in SIRT1 (unknown origin) deacetylation activity at 10 uM2015Journal of natural products, Apr-24, Volume: 78, Issue:4
Bioactive Metabolites from the Fruits of Psoralea corylifolia.
AID714144Antilarval activity against third-instar larvae of Anopheles gambiae assessed as mortality at 1000 ug/L after 72 hrs2012Bioorganic & medicinal chemistry, Mar-01, Volume: 20, Issue:5
Redox potentials, laccase oxidation, and antilarval activities of substituted phenols.
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1312215Substrate activity at mushroom tyrosinase assessed as Kcat/Km ratio for monophenolase activity in presence H2O2 by spectrophotometry based Michaelis-Menten plot analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Characterization of the action of tyrosinase on resorcinols.
AID1366531Cytotoxicity against mpx:GFP transgenic zebrafish 24 hrs post fertilization embryo neutrophils assessed as loss in neutrophil2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID662540Depigmentation activity in mouse Melan-a cells after 4 days by spectrophotometry2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Depigmenting activities of kojic acid derivatives without tyrosinase inhibitory activities.
AID338273Toxicity against Artemia salina after 24 hrs1994Journal of natural products, Dec, Volume: 57, Issue:12
Biological effects of prenylated hydroquinones: structure-activity relationship studies in antimicrobial, brine shrimp, and fish lethality assays.
AID1366399Toxicity in wild type zebrafish embryos assessed as notochord at 20 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID662538Inhibition of mushroom tyrosinase using L-tyrosine as substrate after 20 mins by spectrophotometry2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Depigmenting activities of kojic acid derivatives without tyrosinase inhibitory activities.
AID1366438Toxicity in wild type zebrafish embryos assessed as pericardial edema at 20 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366427Toxicity in wild type zebrafish embryos assessed as otoliths at 10 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID12687781-Octanol-water partition coefficient, log P of the compound by UV spectrophotometry-based shake flask method2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Regulatory effect of hydroquinone-tetraethylene glycol conjugates on zebrafish pigmentation.
AID395021Cytotoxicity against C57BL/6J mouse Melan-a cells assessed as cell survival at 10 uM by modified crystal violet assay2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
Studies on depigmenting activities of dihydroxyl benzamide derivatives containing adamantane moiety.
AID422532Inhibition of melanin synthesis in NHEM after 24 hrs by liquid scintillation2009Journal of natural products, Jan, Volume: 72, Issue:1
Melanin synthesis inhibitors from Lespedeza cyrtobotrya.
AID1291721Protective activity against Daboia russellii venom-induced hemorrhage in Swiss albino mouse at 100 mmol, iv assessed as hemorhagic lesion by measuring minimal hemolytic dose administered immediately after venom injection measured after 24 hrs (Rvb =5 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID342475Inhibition of human carbonic anhydrase 1 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID1366422Toxicity in wild type zebrafish embryos assessed as eyes at 6.25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366428Toxicity in wild type zebrafish embryos assessed as otoliths at 5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID403904Cytotoxicity against african green monkey BSC1 cells at 30 ug/disk1997Journal of natural products, Jun, Volume: 60, Issue:6
Antimicrobial and cytotoxic phenolic glycoside esters from the New Zealand tree Toronia toru.
AID398960Cytotoxicity against human KB cells
AID403618Antimicrobial activity against Escherichia coli at 120 ug/disk1997Journal of natural products, Jun, Volume: 60, Issue:6
Antimicrobial and cytotoxic phenolic glycoside esters from the New Zealand tree Toronia toru.
AID1366343Toxicity in wild type zebrafish embryos assessed as dead embryo at 6.25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID336478Inhibition of COX2 at 100 uM by scintillation proximity assay2002Journal of natural products, Nov, Volume: 65, Issue:11
Screening of ubiquitous plant constituents for COX-2 inhibition with a scintillation proximity based assay.
AID1366460Toxicity in wild type zebrafish embryos assessed as yolk edema at 12.5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1449738Inhibition of Malassezia globosa recombinant beta-carbonic anhydrase preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Inhibition of Malassezia globosa carbonic anhydrase with phenols.
AID331291Inhibition of human carbonic anhydrase 1 by stopped-flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols.
AID714145Antilarval activity against third-instar larvae of Anopheles gambiae assessed as mortality at 50 ug/L after 72 hrs2012Bioorganic & medicinal chemistry, Mar-01, Volume: 20, Issue:5
Redox potentials, laccase oxidation, and antilarval activities of substituted phenols.
AID1366518Toxicity in wild type zebrafish embryos assessed as skeletal deformities at 10 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366388Toxicity in wild type zebrafish embryos assessed as growth retardation at 10 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366401Toxicity in wild type zebrafish embryos assessed as notochord at 10 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366526Toxicity in wild type zebrafish embryos assessed as skeletal deformities at 6.25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366477Toxicity in wild type zebrafish embryos assessed as blood circulation at 20 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366348Cytotoxicity against wild type zebrafish embryo melanocytes assessed as small and rounded cells at 12.5 ug/ml treated for 72 hrs post fertilization starting from 6 to 24 hrs post fertilization2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID338271Antimicrobial activity against Escherichia coli DSM 1103 after 18 hrs by twofold serial dilution method1994Journal of natural products, Dec, Volume: 57, Issue:12
Biological effects of prenylated hydroquinones: structure-activity relationship studies in antimicrobial, brine shrimp, and fish lethality assays.
AID1312213Substrate activity at mushroom tyrosinase assessed as Km for monophenolase activity in presence H2O2 by spectrophotometry based Michaelis-Menten plot analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Characterization of the action of tyrosinase on resorcinols.
AID1366435Toxicity in wild type zebrafish embryos assessed as otoliths at 6.25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366382Toxicity in wild type zebrafish embryos assessed as normal embryo at 12.5 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1366385Toxicity in wild type zebrafish embryos assessed as growth retardation at 25 ug/ml treated for 96 hrs post fertilization starting from 6 hrs post fertilization by inverted microscopic analysis relative to control2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Potent anti-melanogenic activity and favorable toxicity profile of selected 4-phenyl hydroxycoumarins in the zebrafish model and the computational molecular modeling studies.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1798641CA Inhibition Assay from Article 10.1016/j.bmc.2008.06.013: \\Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.\\2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID1803139Esterase Activity Assay from Article 10.3109/14756366.2011.637202: \\Simple methanesulfonates are hydrolyzed by the sulfatase carbonic anhydrase activity.\\2012Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 27, Issue:6
Simple methanesulfonates are hydrolyzed by the sulfatase carbonic anhydrase activity.
AID1799717Enzyme Assay from Article 10.1080/14756360701654894: \\Effects of hydroxybenzyl alcohols on melanogenesis in melanocyte-keratinocyte co-culture and monolayer culture of melanocytes.\\2008Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 23, Issue:4
Effects of hydroxybenzyl alcohols on melanogenesis in melanocyte-keratinocyte co-culture and monolayer culture of melanocytes.
AID1799825Inhibition Assay from Article : \\Partial identity of the 2-oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase.\\1986The Journal of biological chemistry, Jun-15, Volume: 261, Issue:17
Partial identity of the 2-oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2012Chemical communications (Cambridge, England), May-28, Volume: 48, Issue:43
Nucleophile recognition as an alternative inhibition mode for benzoic acid based carbonic anhydrase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,793)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990189 (10.54)18.7374
1990's338 (18.85)18.2507
2000's480 (26.77)29.6817
2010's625 (34.86)24.3611
2020's161 (8.98)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 70.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index70.48 (24.57)
Research Supply Index7.60 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index227.86 (26.88)
Search Engine Supply Index3.62 (0.95)

This Compound (70.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials111 (5.88%)5.53%
Reviews111 (5.88%)6.00%
Case Studies78 (4.13%)4.05%
Observational1 (0.05%)0.25%
Other1,587 (84.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (23)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Controlled, Single Center Clinical Study to Evaluate the Effect of Facial Serum Q69 in Moderating the Appearance of Mild to Moderate Melasma [NCT05013801]96 participants (Actual)Interventional2021-09-06Completed
Randomized, Controlled, Double-blind Study of Oral Tranexamic Acid and Topical Hydroquinone in the Treatment of Melasma [NCT03751163]Phase 350 participants (Actual)Interventional2016-03-16Completed
Efficacy and Safety of a 4% Hydroquinone Cream (Melanoderm 4%) for the Treatment of Melasma: a Randomized Controlled Split-face Study [NCT02095990]Phase 317 participants (Actual)Interventional2014-03-31Completed
Randomized, Double-blinded, Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Subjects With Moderate Facial Melasma [NCT02977507]18 participants (Actual)Interventional2016-12-13Completed
A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma [NCT02110134]6 participants (Actual)Interventional2013-12-31Completed
Compare the Efficacy and Safety Profile of Cysteamine and Hydroquinone in Melasma as Topical Application [NCT05969587]Phase 328 participants (Actual)Interventional2019-11-28Completed
A Clinical Usage Study to Evaluate the Safety and Efficacy of an Herbal-Based De-Pigmenting System [NCT02138539]Phase 428 participants (Actual)Interventional2013-10-31Completed
A Randomized, Observer-Blinded, Vehicle-Controlled Study on the Safety and Efficacy of Twice Daily Application of Ruboxistaurin (DBI-102) Gel Vs.Vehicle Gel Vs. Hydroquinone Cream on Sun-Exposed and Sun-Protected Skin of Adults [NCT05511948]Phase 275 participants (Actual)Interventional2022-08-18Completed
Split-Face, Randomized, Open-Label Study of Sequential Treatment With Tri-Luma® Cream With Intense Pulsed Light (IPL) vs. a Mild Inactive Control Cream With Intense Pulsed Light (IPL) in Subjects With Melasma [NCT00669071]Phase 456 participants (Actual)Interventional2008-01-31Terminated(stopped due to Enrollment closed)
Comparison Of The Efficacy Of Combination Of TAM Formula Versus Kligman Formula For Melasma At Tertiary Care Hospital,Karachi. [NCT06013540]Phase 2122 participants (Actual)Interventional2022-08-01Active, not recruiting
Efficacy of Melanil in the Treatment of Melasma [NCT01001624]Phase 3150 participants (Actual)Interventional2009-10-31Completed
Efficacy & Safety of Azelaic Acid 15% Gel vs. Hydroquinone 4% Cream in the Treatment of Melasma [NCT00927771]Phase 430 participants (Anticipated)Interventional2009-06-30Recruiting
Comparison of Topical Silymarin With Hydroquinone in the Treatment of Melasma [NCT03982849]Phase 292 participants (Actual)Interventional2019-07-15Completed
Efficacy and Safety of Using Combination of 755-nm Picosecond Alexandrite Laser and 2% Hydroquinone Compared With 2% Hydroquinone Alone for the Treatment of Melasma: a Randomized Split-face Controlled Trial [NCT04597203]20 participants (Anticipated)Interventional2020-10-31Recruiting
Oral and 5% Topical Tranexamic Acid in Monotherapy Compared With 4% Topical Hydroquinone for the Treatment of Melasma: Three-arm Randomized, Double-blinded Clinical Trial [NCT03585179]Phase 3120 participants (Anticipated)Interventional2018-08-01Not yet recruiting
Double Blind Randomized Study of 2% Miconazol Versus 4% Hydroquinone in the Treatment for Melasma. [NCT01661556]Phase 460 participants (Anticipated)Interventional2011-10-31Recruiting
Outcomes of Different Biological Therapy on Rheumatoid Arthritis [NCT05267431]200 participants (Anticipated)Observational2022-06-30Not yet recruiting
Prospective Evaluation of Topical Almond Oil vs Hydroquinone on the Appearance of Facial Pigmentation and the Stability of the Microbiome [NCT04875715]Phase 450 participants (Anticipated)Interventional2021-07-01Active, not recruiting
An Assessment of the Atrophogenic Potential of Triple Combination Cream Using Histology Measures in the Treatment of Moderate to Severe Melasma [NCT00469183]Phase 470 participants (Actual)Interventional2006-05-31Completed
A Comparative Study for Efficacy and Safety Between 4% Hydroquinone Cream With or Without Fractional Picosecond 1,064 nm Laser for the Treatment of Dermal or Mixed Type Melasma [NCT03049059]Phase 230 participants (Actual)Interventional2016-06-01Completed
Randomized, Double-Blind Evaluation of Hexyresorcinol vs Hydroquinone for Photoaging [NCT04345094]32 participants (Actual)Interventional2019-07-01Completed
Open Label Study to Evaluate the Efficacy and Safety of Sequential Therapy With Fluocinolone Acetonide 0.01%, Hydroquinone (HQ) 4% and Tretinoin 0.05% (TriLuma® Cream) and a Series of Glycolic Acid Peels for the Treatment of Melasma [NCT00472966]Phase 420 participants (Actual)Interventional2006-11-30Completed
Comparative Efficacy of Azelaic Acid 20% Cream Versus Hydroquinone 4% Cream as an Adjuvant to Oral Tranexamic Acid in Melasma [NCT05887219]Phase 150 participants (Actual)Interventional2022-11-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00669071 (8) [back to overview]Number of Participants With Tolerability Assessments Resulting in Adverse Events
NCT00669071 (8) [back to overview]Degree of Pigmentation (Melanin) Using a Mexameter at Weeks 6 and 10
NCT00669071 (8) [back to overview]Number of Participants Showing Success or Failure in Improvement of Melasma at Week 10 Using the Investigator's Evaluation of Improvement
NCT00669071 (8) [back to overview]Number of Participants Showing Success or Failure in Improvement of Melasma at Week 10 Using the Subject's Evaluation of Improvement
NCT00669071 (8) [back to overview]Number of Participants Showing Success or Failure in Improvement of Melasma at Week 6 Using the Investigator's Evaluation of Improvement
NCT00669071 (8) [back to overview]Number of Participants Showing Success or Failure in Improvement of Melasma at Week 6 Using the Subject's Evaluation of Improvement
NCT00669071 (8) [back to overview]Number of Participants Who Were a Success or Failure With Regards to Melasma Severity at Week 10 as Evaluated Using the Investigator's Global Assessment (IGA) of Melasma
NCT00669071 (8) [back to overview]Number of Participants Who Were a Success or Failure With Regards to Melasma Severity at Week 6 Using the Investigator's Global Assessment (IGA) of Melasma With Clear/Almost Clear Being Success and All Others Being Failure
NCT02977507 (9) [back to overview]Investigator's Global Improvement Assessment for Overall Hyperpigmentation Score to Week 12
NCT02977507 (9) [back to overview]Change From Baseline in Melasma Area and Severity Index (MASI) Score to Week 12
NCT02977507 (9) [back to overview]Change From Baseline in Melasma Quality of Life (MELASQOL) Scale Total Score to Week 12
NCT02977507 (9) [back to overview]Change From Baseline in Melasma Severity Rating Scale Score to Week 12
NCT02977507 (9) [back to overview]Change From Baseline in Mexameter Measurement of Target Hyperpigmentation Lesion to Week 12
NCT02977507 (9) [back to overview]Change From Baseline in Overall Hyperpigmentation Scale Score to Week 12
NCT02977507 (9) [back to overview]Number of Participants by Responses for Self-Assessment Questionnaire: Overall Improvement in Skin Condition
NCT02977507 (9) [back to overview]Number of Participants by Responses for Self-Assessment Questionnaire: Overall Satisfaction With the Test Product
NCT02977507 (9) [back to overview]Number of Participants by Responses for Self-Assessment Questionnaire: Test Product Preference

Number of Participants With Tolerability Assessments Resulting in Adverse Events

Number of participants with Tolerability assessments (erythema, scaling, dryness, stinging/burning, edema, telangiectasis, darkening or melasma spots) resulting in adverse events (NCT00669071)
Timeframe: Baseline to week 10

Interventionparticipants (Number)
Intense Pulsed Light (IPL) / Tri-Luma® Cream1
Intense Pulsed Light (IPL) / Inactive Control Cream0

[back to top]

Degree of Pigmentation (Melanin) Using a Mexameter at Weeks 6 and 10

Degree of pigmentation (melanin) using a Mexameter to record units on a scale at Weeks 6 and 10; units on a scale is a number that represents the presence or absence of melanin in the skin on a scale from 0 - 999 units with 0 units representing no melanin and 999 units representing the maximum amount of melanin. (NCT00669071)
Timeframe: Baseline to Week 6 and Baseline to Week 10

,
Interventionunits on a scale (Mean)
Week 6Week 10
Intense Pulsed Light (IPL) / Inactive Control Cream36.726.2
Intense Pulsed Light (IPL) / Tri-Luma® Cream27.515.1

[back to top]

Number of Participants Showing Success or Failure in Improvement of Melasma at Week 10 Using the Investigator's Evaluation of Improvement

Number of participants showing success or failure in improvement of melasma at Week 10 using the Investigator's evaluation of improvement (0 = Worse, 1 = No change, 2 = Improved, 3 = Much improved, 4 = Excellent Improvement) with Improved, Much improved and Excellent Improvement defined as success and Worse or No change being defined as failure (NCT00669071)
Timeframe: Baseline to week 10

,
Interventionparticipants (Number)
SuccessFailureMissing
Intense Pulsed Light (IPL) / Inactive Control Cream37163
Intense Pulsed Light (IPL) / Tri-Luma® Cream4493

[back to top]

Number of Participants Showing Success or Failure in Improvement of Melasma at Week 10 Using the Subject's Evaluation of Improvement

Number of participants showing success or failure in improvement of melasma at Week 10 using the Subject's evaluation of improvement (0 = Worse, 1 = No change, 2 = Improved, 3 = Much improved, 4 = Excellent Improvement) with Improved, Much improved and Excellent Improvement defined as success and Worse or No change being defined as failure (NCT00669071)
Timeframe: Baseline to week 10

,
Interventionparticipants (Number)
SuccessFailureMissing
Intense Pulsed Light (IPL) / Inactive Control Cream36173
Intense Pulsed Light (IPL) / Tri-Luma® Cream4853

[back to top]

Number of Participants Showing Success or Failure in Improvement of Melasma at Week 6 Using the Investigator's Evaluation of Improvement

Number of participants showing success or failure in improvement of melasma at Week 6 using the Investigator's evaluation of improvement (0 = Worse, 1 = No change, 2 = Improved, 3 = Much improved, 4 = Excellent Improvement) with Improved, Much improved and Excellent Improvement defined as success and Worse or No change being defined as failure (NCT00669071)
Timeframe: Baseline to week 6

,
Interventionparticipants (Number)
SuccessFailureMissing
Intense Pulsed Light (IPL) / Inactive Control Cream40133
Intense Pulsed Light (IPL) / Tri-Luma® Cream4673

[back to top]

Number of Participants Showing Success or Failure in Improvement of Melasma at Week 6 Using the Subject's Evaluation of Improvement

Number of participants showing success or failure in improvement of melasma at Week 6 using the Subject's evaluation of improvement (0 = Worse, 1 = No change, 2 = Improved, 3 = Much improved, 4 = Excellent Improvement) with Improved, Much improved and Excellent Improvement defined as success and Worse or No change being defined as failure (NCT00669071)
Timeframe: Baseline to week 6

,
Interventionparticipants (Number)
SuccessFailureMissing
Intense Pulsed Light (IPL) / Inactive Control Cream33203
Intense Pulsed Light (IPL) / Tri-Luma® Cream4853

[back to top]

Number of Participants Who Were a Success or Failure With Regards to Melasma Severity at Week 10 as Evaluated Using the Investigator's Global Assessment (IGA) of Melasma

Number of participants who were a success or failure with regards to melasma severity at Week 10 as evaluated using the Investigator's Global Assessment (IGA) of melasma (0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate, 4 = Severe) with Clear / Almost Clear being success and all others being failure (NCT00669071)
Timeframe: Baseline to week 10

,
Interventionparticipants (Number)
SuccessFailureMissing
Intense Pulsed Light (IPL) / Inactive Control Cream13430
Intense Pulsed Light (IPL) / Tri-Luma® Cream32240

[back to top]

Number of Participants Who Were a Success or Failure With Regards to Melasma Severity at Week 6 Using the Investigator's Global Assessment (IGA) of Melasma With Clear/Almost Clear Being Success and All Others Being Failure

Number of participants who were a success or failure with regards to melasma severity at Week 6 as evaluated using the Investigator's Global Assessment (IGA) of melasma (0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate, 4 = Severe) with Clear / Almost Clear being success and all others being failure (NCT00669071)
Timeframe: Baseline to week 6

,
Interventionparticipants (Number)
SuccessFailureMissing
Intense Pulsed Light (IPL) / Inactive Control Cream8480
Intense Pulsed Light (IPL) / Tri-Luma® Cream23330

[back to top]

Investigator's Global Improvement Assessment for Overall Hyperpigmentation Score to Week 12

Investigator's global improvement assessment score was used for assessment of overall hyperpigmentation on the left and right facial sides. The score ranged from 0 to 4 where, 0=No change or worsening, 1=Mild improvement (approximately 25% overall improvement), 2=Moderate improvement (approximately 50% overall improvement), 3=Marked improvement (approximately 75% overall improvement), 4=Complete clearing/Dramatic improvement (approximately 95% plus overall improvement). The mean score for overall hyperpigmentation was reported. (NCT02977507)
Timeframe: Week 12

Interventionscore on a scale (Mean)
Lytera 2.01.1
4% Hydroquinone Topical Cream1.8

[back to top]

Change From Baseline in Melasma Area and Severity Index (MASI) Score to Week 12

The investigator assigned a grade for the left and right facial sides for each of the following: A=Total Area Involved (0=No involvement to 6=90 to 100% involvement); D=Darkness of Pigment (0=Normal skin color to 4=Severe hyperpigmentation); and H=Homogeneity (0=Normal skin color without evidence of hyperpigmentation to 4=Uniform skin involvement without any clear areas). Total Half-Face MASI score was calculated as: Half Forehead 0.15(D+H)A + One Malar Side 0.3 (D+H)A + Half Chin 0.05(D+H)A. A negative change from Baseline indicates improvement. (NCT02977507)
Timeframe: Baseline (Day1) to Week 12

,
Interventionscore on a scale (Mean)
BaselineChange from Baseline to Week 12
4% Hydroquinone Topical Cream8.9-3.1
Lytera 2.09.0-1.2

[back to top]

Change From Baseline in Melasma Quality of Life (MELASQOL) Scale Total Score to Week 12

The Melasma Quality of Life Scale assesses the effect melasma has on the quality of life of sufferers on a scale of 1 (not bothered at all) to 7 (bothered all of the time), rating the following questions: 1.The appearance of your skin condition 2.Frustration about your skin condition. 3.Embarrassment about your skin condition. 4.Feeling depressed about your skin condition. 5.The effects of your skin condition on your interactions with other people. 6.The effects of your skin condition on your desire to be with people. 7.Your skin condition making it hard to show affection. 8.Skin discoloration making you feel unattractive to others. 9.Skin discoloration making you feel less vital or productive. 10.Skin discoloration affecting your sense of freedom. The MELASQOL is scored from 7 to 70, with a higher score indicating worse melasma-related health-related quality of life. A negative change from Baseline indicates improvement. (NCT02977507)
Timeframe: Baseline (Day 1) to Week 12

,
Interventionscore on a scale (Mean)
BaselineChange from Baseline to Week 12
4% Hydroquinone Topical Cream46.2-21.7
Lytera 2.045.9-15.0

[back to top]

Change From Baseline in Melasma Severity Rating Scale Score to Week 12

The investigator assessed the participant's facial skin for the severity of symmetrical facial melasma on the left and the right side of the face using the Melasma Severity Rating Scale. The score ranges from 0 to 3, where 0=Cleared: color of melasma lesions approximately equivalent to surrounding normal skin or with minimal residual hyperpigmentation, 1=Mild: color slightly darker than the surrounding normal skin, 2=Moderate: color moderately darker than the surrounding normal skin and 3=Severe: color markedly darker than the surrounding normal skin. A negative change from Baseline indicates improvement. (NCT02977507)
Timeframe: Baseline (Day 1) to Week 12

,
Interventionscore on a scale (Mean)
BaselineChange from Baseline to Week 12
4% Hydroquinone Topical Cream2.1-0.8
Lytera 2.02.1-0.3

[back to top]

Change From Baseline in Mexameter Measurement of Target Hyperpigmentation Lesion to Week 12

"Two target hyperpigmented lesions were selected from the left and the right malar facial areas and were measured by the mexameter, an instrument that measures melanin content. One target normal measurement was also taken from an unaffected skin area on the face representing normal skin. The values from the target hyperpigmented lesions were compared to the normal lesion value. The range of melamin index and erythema is 0 to 999 Arbitrary Units (AU). A negative change from Baseline indicates improvement." (NCT02977507)
Timeframe: Baseline (Day 1) to Week 12

,,
InterventionAU (Mean)
Baseline (Melanin index)Change from Baseline to Week 12 (Melanin index)Baseline (Erythema)Change from Baseline to Week 12 (Erythema)
4% Hydroquinone Topical Cream587.1-26.5584.5-0.1
Lytera 2.0581.1-3.0578.93.4
Normal Skin544.5-2.4572.79.4

[back to top]

Change From Baseline in Overall Hyperpigmentation Scale Score to Week 12

The investigator assessed the participant's left and right facial sides for overall hyperpigmentation using the Overall Hyperpigmentation ten-point scale ranging from 0 to 9, where Score 0=None, skin is normal in color with no evidence of hyperpigmentation; Score 1, 2 or 3=Mild, several brown spots with increased pigmentation, they are small in size and slightly darker than surrounding skin; Score 4, 5 or 6=Moderate, many brown spots with increased pigmentation, they are medium in size and much darker than surrounding skin; Score of 7, 8 or 9=Severe, many large brown spots with increased pigmentation, they are large in size and markedly darker than surrounding skin. A negative change from Baseline indicates improvement. (NCT02977507)
Timeframe: Baseline (Day 1) to Week 12

,
Interventionscore on a scale (Mean)
BaselineChange from Baseline to Week 12
4% Hydroquinone Topical Cream4.8-1.7
Lytera 2.04.8-0.8

[back to top]

Number of Participants by Responses for Self-Assessment Questionnaire: Overall Improvement in Skin Condition

Using the Subject Self-Assessment Questionnaire: Overall Improvement, the participant selected a response that best represented their feelings on the overall improvement in their skin condition compared to the beginning of the study. Responses were categorized as: 0=No change or a worsening in my skin condition (dark areas of color on skin), 1=I see a slight improvement in my skin condition (approximately 25% overall improvement), 2=I see a moderate improvement in my skin condition (approximately 50% overall improvement), 3=I see a marked improvement in my skin condition (approximately 75% overall improvement), 4=I see a complete clearing of my skin condition (approximately 95% or better overall improvement). (NCT02977507)
Timeframe: Baseline (Day 1) to Weeks 4, 8 and 12

,
InterventionParticipants (Count of Participants)
Week 4: 0- No changeWeek 4: 1- Slight improvementWeek 4: 2- Moderate improvementWeek 4: 3- Marked improvementWeek 4: 4- Complete clearing of skinWeek 8: 0- No changeWeek 8: 1- Slight improvementWeek 8: 2- Moderate improvementWeek 8: 3- Marked improvementWeek 8: 4- Complete clearing of skinWeek 12: 0- No changeWeek 12: 1- Slight improvementWeek 12: 2- Moderate improvementWeek 12: 3- Marked improvementWeek 12: 4- Complete clearing of skin
4% Hydroquinone Topical Cream2113200544312382
Lytera 2.0583102732242550

[back to top]

Number of Participants by Responses for Self-Assessment Questionnaire: Overall Satisfaction With the Test Product

Using the Subject Self-Assessment Questionnaire: Satisfaction with Treatment, the participant selected a response that best represented their overall satisfaction with the test product. Responses were categorized as: 1=Excellent (very satisfied), 2=Good (moderately satisfied), 3=Fair (slightly satisfied) and 4=Poor (not satisfied at all). (NCT02977507)
Timeframe: Weeks 4, 8 and 12

,
InterventionParticipants (Count of Participants)
Week 4: 1- Excellent (very satisfied)Week 4: 2- Good (moderately satisfied)Week 4: 3- Fair (slightly satisfied)Week 4: 4- Poor (not satisfied at all)Week 8: 1- Excellent (very satisfied)Week 8: 2- Good (moderately satisfied)Week 8: 3- Fair (slightly satisfied)Week 8: 4- Poor (not satisfied at all)Week 12: 1- Excellent (very satisfied)Week 12: 2- Good (moderately satisfied)Week 12: 3- Fair (slightly satisfied)Week 12: 4- Poor (not satisfied at all)
4% Hydroquinone Topical Cream693078105821
Lytera 2.0395147415263

[back to top]

Number of Participants by Responses for Self-Assessment Questionnaire: Test Product Preference

Using the Subject Self-Assessment Questionnaire: Facial Side Preference, the participant selected based on their experience, the Test Product they preferred to use. (NCT02977507)
Timeframe: Weeks 4, 8 and 12

,
InterventionParticipants (Count of Participants)
Week 4Week 8Week 12
4% Hydroquinone Topical Cream121313
Lytera 2.0633

[back to top]